Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Spondyloepiphyseal Dysplasia Congenita. Core disease mechanisms, molecular...

This report is retrieval-only and is generated directly from Asta results.

• Papers retrieved: 18
• Snippets retrieved: 20

Relevant Papers

[1] Exploring and expanding the phenotype and genotype diversity in seven Chinese families with spondylo-epi-metaphyseal dysplasia

• Authors: Shanshan Lv, Jiao Zhao, Li Liu, C. Wang, H. Yue et al.
• Year: 2022
• Venue: Frontiers in Genetics
• URL: https://www.semanticscholar.org/paper/9a62aa326fc1ed5c4ff713faa72491102dd12c0f
• DOI: 10.3389/fgene.2022.960504
• PMID: 36118854
• PMCID: 9473317
• Citations: 2
• Summary: The phenotype and genetic spectrum of SEMD is expanded and evidence for the phenotype–genotype relations is provided, aiding future molecular and clinical diagnosis as well as procreative management of SEMd.
• Evidence snippets:
• Snippet 1 (score: 0.579) > For example, SED with different clinical manifestations can be divided into spondyloepiphyseal dysplasia congenita (SEDC, OMIM# 183900), spondyloepiphyseal dysplasia-Kimberley type (SED-KT, OMIM# 608361), and spondyloepiphyseal dysplasia-Maroteaux type (SED-MT, OMIM# 184095). > So far, more than 30 pathogenic genes have been identified to cause SEMD. These disease-causing genes are involved in encoding various types and functions of proteins (Cormier-Daire, 2008). It is difficult to define them as a common signal pathway among all the SEMD. In such clinical and genetic heterogeneous diseases, different gene-disease associations and overlapping clinical characteristics of different genes complicate the differential diagnosis. According to the nosology and classification of genetic skeletal disorders 2019 revision, groups 10-13 are classified as spondylo-epi-metaphyseal abnormalities, but these diseases still exist in other groups (Mortier et al., 2019). The more common SEMD were COL2A1-related dysplasia and pseudoachondroplasia (OMIM# 177170). > At present, most of the reports of SEMD are single case reports, and there are few studies focusing on exploring the phenotype of SEMD caused by different disease-causing genes. We reported seven families with SEMD caused by TRPV4, COL2A1, CCN6, SBDS, and ACAN genes in order to explore the relationship between phenotype and genotype of them. Several studies have reported the phenotype-genotype relations of skeletal disorders caused by COL2A1, COMP, and CCN6 genes (Barat-Houari et al., 2016a;Madhuri et al., 2016;Liang et al., 2021), but we still need more families to prove it, especially Chinese families. Therefore, we summarized the clinical manifestations, radiological data, and molecular features of patients with SEMD, hoping to improve our understanding of Chinese families with SEMD.
• Snippet 2 (score: 0.566) > Spondylo-epi-metaphyseal dysplasia (SEMD) is a heterogeneous genetic disorder, involving vertebral, epiphyseal, and metaphyseal dysplasia, and is diagnosed based on clinical phenotype, radiographic examination, and molecular sequencing. The primary clinical feature is a different degree of short stature (may present with short limbs or short trunk), combined with specific orthopedic symptoms (such as developmental coxa vara and scoliosis). Epiphyseal dysplasia usually leads to early-onset osteoarthritis, mostly in weightbearing joints (Briggs et al., 1995). Odontoid hypoplasia causes atlantoaxial instability with severe spinal compression problems (Miyoshi et al., 2004). Radiological features included platyspondyly, vertebral body irregularity, destruction of articular cartilage, and dysplasia of epiphysis and metaphysis (Spranger, 1989). > This category of diseases is usually given the nomenclature according to the site name of manifest radiographic abnormalities (Alanay and Lachman, 2011;Mortier et al., 2019) (Figure 1), including spondyloepiphyseal dysplasia (SED), spondylometaphyseal dysplasia (SMD), spondyloepi-metaphyseal dysplasia (SEMD), metaphyseal dysplasia (MD), and epiphyseal dysplasia (ED). With the in-depth study, SEMD is further classified according to specific clinical manifestations. For example, SED with different clinical manifestations can be divided into spondyloepiphyseal dysplasia congenita (SEDC, OMIM# 183900), spondyloepiphyseal dysplasia-Kimberley type (SED-KT, OMIM# 608361), and spondyloepiphyseal dysplasia-Maroteaux type (SED-MT, OMIM# 184095).

[2] X‐linked spondyloepiphyseal dysplasia tarda: Novel and recurrent mutations in 13 European families

• Authors: J. Fiedler, M. Merrer, G. Mortier, S. Heuertz, L. Faivre et al.
• Year: 2004
• Venue: Human Mutation
• URL: https://www.semanticscholar.org/paper/252156da9f4936fffde8fe2cbd01c107853b6f4d
• DOI: 10.1002/humu.9254
• PMID: 15221797
• Citations: 25
• Summary: All sequence variations identified are either deletions of complete exons or predicted to result in a premature stop codon or to lead into splicing defects and are associated with a loss of considerable parts of the sedlin protein.
• Evidence snippets:
• Snippet 1 (score: 0.577) > The term spondyloepiphyseal dysplasia (SED) refers to a heterogeneous group of skeletal dysplasias with mainly involvement of the epiphyses and vertebral bodies on radiographs. Patients usually have short stature and early development of degenerative joint disease. SED has been divided into a congenita and a tarda form according to the age of onset and clinical severity. The different modes of inheritance within the group of SEDs reflect the genetic heterogeneity. Autosomal dominant, autosomal recessive and X-linked recessive patterns of inheritance have been described. In autosomal dominant forms of SED congenita (MIM# 183900) (Spranger et al., 1994) and spondyloepimetaphyseal dysplasia (SEMD; MIM# 184250) Strudwick type (Tiller et al., 1995) mutations in the type II collagen gene (COL2A1), the most abundant collagen of cartilage, have been identified. In another autosomal recessive form of SEMD, mutations have been described in the ATPSK2 gene that is involved in sulfation of proteoglycans (ul Haque et al., 1998). > X-linked spondyloepiphyseal dysplasia tarda (SEDT; MIM# 313400) is characterized by moderate short stature, barrel chest deformity and minor epiphyseal abnormalities. The diagnosis is usually made based on the characteristic vertebral body dysplasia comprising platyspondyly and a central hump (Iceton and Horne, 1986;Whyte et al., 1999). Degenerative joint disease is a common problem in male patients making joint replacement of the hips often necessary in the fourth or fifth decade. The gene causing SEDT (SEDL; MIM# 300202; RefSeq ID: NM_014563.2) was mapped to Xp22 (Szpiro-Tapia et al., 1988). The SEDL gene contains 6 exons and spans a genomic region of approximately 20kb.

[3] Novel COL2A1 variants in Japanese patients with spondyloepiphyseal dysplasia congenita

• Authors: M. Akahira-Azuma, Yumi Enomoto, N. Nakamura, Takayuki Yokoi, Mari Minatogawa et al.
• Year: 2022
• Venue: Human Genome Variation
• URL: https://www.semanticscholar.org/paper/a175a7bef26158a684828ec52f143367c61342d0
• DOI: 10.1038/s41439-022-00193-x
• PMID: 35581182
• PMCID: 9114327
• Citations: 3
• Summary: The genotype-phenotype correlations in five Japanese patients with SEDC are reported based on their clinical and radiological findings and it is found that all five patients had novel missense variants resulting in glycine substitutions.
• Evidence snippets:
• Snippet 1 (score: 0.535) > . Our five patients also presented with variable nonskeletal complications, suggesting the importance of genetic diagnosis for early intervention and prevention. However, it is difficult to establish clear rules for a genotype-phenotype correlation in SEDC. Other genetic or nongenetic factors could be involved that have not yet been discovered. > In conclusion, genetic testing can provide definitive diagnosis in patients with SEDC. Since the different manifestations may involve not only domain-specific but also codon-specific underlying mechanisms, it would be extremely useful to accumulate information on the correlation between pathogenic variants and clinical features as well as prognosis in these patients. Fig. 1 Clinical and genetic findings of five children with spondyloepiphyseal dysplasia congenita. A Distribution of the six novel COL2A1 variants that were identified. B Growth charts (Japanese version 2020) for Patients 2, 3, and 5. C Skeletal survey for Patient 2. Radiographic findings included significant platyspondyly, shortening of long bones with ragged metaphyses, mild iliac hypoplasia, and delayed ossification of the femur head.

[4] Identification of a New Variant of the MBTPS1 Gene of the Kondo-Fu Type of Spondyloepiphyseal Dysplasia (SEDKF) in a Saudi Patient

• Authors: Maha Alotaibi, Ali M Aldossari, I. Khan, Leena Alotaibi
• Year: 2022
• Venue: Case Reports in Pediatrics
• URL: https://www.semanticscholar.org/paper/f9b83c984a2c14a5556b0b3648a0c5de8cc5cb55
• DOI: 10.1155/2022/5498109
• PMID: 36330313
• PMCID: 9626241
• Citations: 3
• Summary: Considering clinical phenotypes and radiological findings produced by the pathogenic mutation in the MBTPS1 gene, the identified c.2634C > A variant is supported and may be categorized as likely pathogenic based on clinical symptoms.
• Evidence snippets:
• Snippet 1 (score: 0.530) > Skeletal dysplasia is a heterogeneous group of bone growth disorder, nonfatal, presented as short stature and skeletal deformities [4]. Clinically and genetically, these disorders vary widely. While some spondyloepiphyseal dysplasia, such as spondyloepiphyseal dysplasia congenita (SEDC), appear during pregnancy, others do so during childhood. > e Kondo-Fu form of spondyloepiphyseal dysplasia SEDKF is one of the rare disorders that come under the umbrella of skeletal dysplasia. One patient with SEDKF was included in our investigation. Short trunk and intellectual impairment are all manifestations of SEDKF. Dysmorphic facial features, kyphosis, pectus carinatum, and bone deformity are further SEDKF symptoms. During the clinical valuation of our patient, including body examination and radiological investigations, we did not manifest bilateral cataract and inguinal hernia. > Membrane-bound transcription factor site-1 protease (MBTPS1) is an enzyme encoded by the MBTPS1 gene in humans. S1P cleaves the transcriptional regulators of the sterol regulatory element-binding protein's endoplasmic reticulum loop (SREBP) [5]. Due to genetic abnormalities in key regulators of the secretory apparatus, MBTPS1-related disorders are a category of hereditary diseases defined by secretion deficits in chondrocytes in cartilage, resulting in skeletal dysplasia and eventual growth retardation. If too much collagen is not released from cells and eventually accumulates within the cells, the skeletal organs can malfunction. > Spondyloepiphyseal dysplasia of the Kondo-Fu type (SEDKF) is a rare autosomal recessive disorder caused by a mutation in the MBTPS1 gene that results in short stature and other phenotypes such as a triangular face, spondyloepiphyseal dysplasia, kyphosis, growth retardation, delayed motor milestones, and elevated lysosomal enzymes.

[5] EndoCompass Project: Research Roadmap for Calcium and Bone Endocrinology

• Authors: K. Jähn-Rickert, K. Z. Tomsic, A. Anastasilakis, Jean-Philippe Bertocchio, M. L. Brandi et al.
• Year: 2025
• Venue: Hormone Research in Pædiatrics
• URL: https://www.semanticscholar.org/paper/fccbdcae3a86c448632e05f9c38ad2563c14284d
• DOI: 10.1159/000549160
• PMID: 41296665
• PMCID: 12698132
• Summary: This framework identifies crucial investigation areas into metabolic bone disease pathophysiology, prevention, and treatment strategies, ultimately aimed at reducing the burden of these disorders on individuals and society.
• Evidence snippets:
• Snippet 1 (score: 0.527) > Skeletal dysplasias encompass a large spectrum of genetic disorders of the skeleton with abnormal bone growth, structure, or strength [85]. Individually, they are rare but, collectively, due to the large number of skeletal dysplasias (>700), they result in significant morbidity. The underlying pathology remains inadequately understood and the optimal therapy is often undefined, with precision drug treatment targeting the underlying molecular mechanism not available for most skeletal dysplasias. Gene discoveries have increased exponentially, demonstrating the value of advanced genetic tools and motivating further research into the complex pathogenesis of skeletal dysplasias. > However, further basic research is required to uncover the cellular pathology and implicated molecular pathways in various forms of skeletal dysplasia. Understanding the pathophysiology of skeletal dysplasias may also benefit a larger patient population. This is evidenced by anti-sclerostin treatment for osteoporosis [86] which, at present, is in clinical trials for osteogenesis imperfecta. Preclinical data show positive effects on bone mass and strength [87]. > The spectrum of disease manifestations of various skeletal dysplasias in different phases of life and health projections across the life course remain inadequately studied. Research on therapeutic approaches needs to focus not only on correcting the pathophysiology but also, more broadly, on surgical approaches, rehabilitation, functional/environmental adaptations, preventative measures, pain management, psychological support, and quality of life. Patient groups must be involved in identifying these research goals. International registries should be utilized to collect and analyse such data. > A multidisciplinary approach is of particular importance in genetic skeletal disorders, to enable cohesive care throughout the life course. The patients have a range of physical impairments due to their skeletal disorder, but also a disease-specific spectrum of extraskeletal manifestations requiring medical attention. These may include, for example, dental and oral health problems, immune deficiency, impaired hearing, and neurological or ophthalmologic manifestations.

[6] Mutation Update for COL2A1 Gene Variants Associated with Type II Collagenopathies

• Authors: M. Barat-Houari, G. Sarrabay, V. Gatinois, A. Fabre, B. Dumont et al.
• Year: 2016
• Venue: Human Mutation
• URL: https://www.semanticscholar.org/paper/9ded412dd4d40669a5a4f364f1f7b3c16d67c645
• DOI: 10.1002/humu.22915
• PMID: 26443184
• Citations: 139
• Influential citations: 7
• Summary: A review of COL2A1 mutations extracted from the Leiden Open Variation Database (LOVD) that was updated with data from PubMed and patients to provide support and potential collaborative material for scientific and clinical projects aimed at elucidating phenotype–genotype correlation and differential diagnosis in patients with type II collagenopathies.
• Evidence snippets:
• Snippet 1 (score: 0.518) > Mutations in type II collagen cause a spectrum of autosomaldominant conditions characterized by skeletal dysplasia [Nishimura et al., 2005;Kannu et al., 2011a] (Table 1). Achondrogenesis type II, hypochondrogenesis, and Torrance type platyspondylic dysplasia Additional Supporting Information may be found in the online version of this article. * Correspondence to: Isabelle Touitou, Hôpital Arnaud de Villeneuve, CHRU Montpellier-Université Montpellier 1, INSERM U844, Unité médicale des maladies auto-inflammatoires, 371, av doyen giraud, Montpellier 34295, France. E-mail: > isabelle.touitou@inserm.fr are the most severe phenotypes and are associated with neonatal death. Spondyloepiphyseal dysplasia congenita (SEDC), spondyloepimetaphyseal dysplasia (SEMD) Strudwick type, Kniest dysplasia, spondyloperipheral dysplasia, and Czech dysplasia are phenotypes of intermediate severity. The milder forms encompass early-onset osteoarthritis and Stickler syndrome type I, which is the most frequent type II collagenopathy (1/10,000). The nonlethal diseases may occur at various ages, and early disease onset results in short stature, whereas later onset presents as isolated joint disease or as an ocular phenotype. > The COL2A1 gene (MIM #108300) encodes the alpha 1 chain of procollagen type II. Molecular defects in this gene cause type II collagenopathies Spranger et al., 1994], and genetic diagnosis is routinely provided [Williams et al., 1992;Richards et al., 2006]. An assessment of the clinical significance of COL2A1 variants is critical to providing accurate genetic counseling for affected families. There is no recent COL2A1 mutation review article in the literature. Here, we provide an exhaustive description of the mutations found in this gene from all available sources, including PubMed, online databases, and our own data [

[7] Novel COL2A1 variants in Japanese patients with spondyloepiphyseal dysplasia congenita

• Authors: M. Akahira-Azuma, Yumi Enomoto, N. Nakamura, Takayuki Yokoi, Mari Minatogawa et al.
• Year: 2022
• Venue: Human Genome Variation
• URL: https://www.semanticscholar.org/paper/814f10a15fefd149f067b4c28959d955ab66c93e
• DOI: 10.1038/s41439-022-00193-x
• Summary: The genotype-phenotype correlations in five Japanese patients with SEDC based on their clinical and radiological findings suggest novel missense variants resulting in glycine substitutions are important for early intervention for the extraskeletal complications of S EDC.
• Evidence snippets:
• Snippet 1 (score: 0.517) > Spondyloepiphyseal dysplasia congenita (SEDC) is a multisystemic skeletal disorder caused by pathogenic variants in COL2A1. Here, we report the genotype-phenotype correlations in five Japanese patients with SEDC based on their clinical and radiological findings. All five patients had novel missense variants resulting in glycine substitutions (G474V, G543E, G567S, G594R, and G1170R). Genetic testing is important for early intervention for the extraskeletal complications of SEDC. Spondyloepiphyseal dysplasia congenita (SEDC) (OMIM#183900) is an autosomal dominant chondrodysplasia characterized by disproportionate short stature, abnormal epiphyses, flattened vertebral bodies (skeletal abnormalities), and extraskeletal features, including myopia, retinal degeneration with retinal detachment, and cleft palate. SEDC is caused by a heterozygous variant in the collagen II alpha 1 (COL2A1) gene.

[8] Diagnostic Challenge of Phenotypic Variability in COL2A1-related Disorders: Four Novel Variants That Expand the Clinical Spectrum

• Authors: Burcu Yeter, Y. Demirkol, Metin Eser, A. H. Akgülle, B. Sözeri et al.
• Year: 2025
• Venue: Journal of Clinical Research in Pediatric Endocrinology
• URL: https://www.semanticscholar.org/paper/64e575d805d829f26319a1cde6343dff23f9b720
• DOI: 10.4274/jcrpe.galenos.2025.2024-9-7
• PMID: 39849673
• PMCID: 12372628
• Citations: 1
• Summary: The clinical, radiological, and molecular findings of patients with COL2A1-related dysplasia are described and the phenotype-genotype correlation is investigated to investigate the phenotype-genotype correlation.
• Evidence snippets:
• Snippet 1 (score: 0.503) > Objective Heterozygous COL2A1 gene mutations are associated with type 2 collagenopathies, characterized by a wide, diverse, and overlapping clinical spectrum in related diseases. Our goal is to describe the clinical, radiological, and molecular findings of patients with COL2A1-related dysplasia and investigate the phenotype-genotype correlation. We also highlight the challenge of categorizing COL2A1-related diseases with similar clinical and radiological phenotypes. Methods Six patients from five unrelated families presented with disproportionate short stature.delayed motor milestones, waddling gait, normal intelligence, and similar radiological features, including delayed epiphyseal ossification, epimetaphyseal changes, scoliosis, lordosis, and platyspondyly. All underwent whole exome sequencing. Demographic, clinical, laboratory, and radiological data were retrospectively obtained from hospital records. Segregation analysis was conducted using Sanger sequencing in all patients. Results Based on clinical, radiological, and molecular results, the six patients were categorized into kniest dysplasia, spondyloepiphyseal dysplasia congenita, and spondyloepimetaphyseal dysplasia Strudwick type. Four novel variants (c.1023+2T>C, p.Gly465Asp, p.Gly855Asp, p.Gly669Ala) were identified in the COL2A1 gene. Conclusion Accurate classification of type 2 collagenopathies is vital to provide appropriate genetic counseling. Predicting extraskeletal manifestations and reducing morbidity through early diagnosis and treatment will significantly improve the quality of life for patients.
• Snippet 2 (score: 0.453) > The disease spectrum ranges from only osteoarthritis with normal stature or ocular complications and hearing loss to severe micromelia, dwarfism, and perinatal lethality. Achondrogenesis type 2 (ACG2) or hypochondrogenesis (HCG) and platyspondylic skeletal dysplasia Torrance type are perinatal lethal forms; kniest dysplasia (KD), spondyloepiphyseal dysplasia congenita (SEDC), spondyloepimetaphyseal dysplasia (SEMD) Strudwick type, spondyloepiphyseal dysplasia Stanescu type and spondyloperipheral dysplasia are moderate forms; epiphyseal dysplasia multiple with myopia and deafness, vitreoretinopathy with phalangeal epiphyseal dysplasia, avascular necrosis of the femoral head, Czech dysplasia, Legg-Calve-Perthes disease, osteoarthritis with mild chondrodysplasia, Stickler syndrome type 1 (STL1), and non-syndromic ocular STL1 are mild forms (4). While the overall prevalence remains unknown, the estimated incidence worldwide ranges from 20.4 to 35.9/100,000 across various locations and populations (5). Due to COL2A1 mutations leading to different phenotypes, even within the same family, clinical variability is observed. > In general, when type 2 collagenopathies are mentioned, the first things that come to mind are short trunk dwarfism, eye involvement (myopia and vitreoretinal detachment), hearing loss, and joint pain. Cleft palate, midface hypoplasia, and micrognathia may also be considered dysmorphic facial features. Radiographic manifestations include platyspondyly, irregular vertebral endplates, kyphosis, lordosis, delayed epiphyseal ossification, and epimetaphyseal changes.

[9] New therapeutic targets in rare genetic skeletal diseases

• Authors: M. Briggs, Peter A. Bell, M. Wright, K. A. Pirog
• Year: 2015
• Venue: Expert Opinion on Orphan Drugs
• URL: https://www.semanticscholar.org/paper/1363107f71ae6d2d60abca471cddf3da5d13644b
• DOI: 10.1517/21678707.2015.1083853
• PMID: 26635999
• PMCID: 4643203
• Citations: 37
• Influential citations: 1
• Summary: An overview of disease mechanisms that are shared amongst groups of different GSDs and potential therapeutic approaches that are under investigation are described to generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.
• Evidence snippets:
• Snippet 1 (score: 0.496) > proteins of the cartilage ECM such as type II collagen [50]. However, emerging knowledge suggests that the primary genetic defect may be less important than the cells' response to the expression of the mutant gene product [107]. Moreover, the largely overlooked response of a cell (i.e. chondrocyte) to the abnormal extracellular environment is also important for disease progression as illustrated by several GSDs discussed in this review. > It is important that 'omics'-based approaches and technologies are systematically applied to the study of rare GSDs so that definitive reference profiles and disease signatures are generated for each phenotype. These can then be used in a Systems Biology approach to identify both common and dissimilar pathological signatures and disease mechanisms. This approach is entirely dependent upon relevant in vitro and in vivo models (and also novel 'disease-mechanism phenocopies' [107]) for testing new diagnostic and prognostic tools and for determining the molecular mechanisms that underpin the pathophysiology so that effective therapeutic treatments can be developed and validated. This approach will eventually lead to personalized treatments and care strategies centred on shared disease mechanisms with the use of relevant biomarkers to monitor the efficacy of treatment and disease progression. > It is vital that all relevant stakeholders are involved from the outset in defining the appropriate outcomes of any potential therapeutic regime. The perceptions of a successful therapy can differ widely between the clinical academic community and the relevant patient-support groups and it is vital that there is engagement on all these issues. > In summary, the identification of causative genes and mutations for GSDs over the last 20 years, coupled with the generation and in-depth analysis of a plethora of relevant cell and mouse models, has derived new knowledge on disease mechanisms and suggested potential therapeutic targets. The fast-evolving hypothesis that clinically disparate diseases can share common disease mechanisms is a powerful concept that will generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.

[10] Skeletal Dysplasias Caused by Sulfation Defects

• Authors: Chiara Paganini, Chiara Gramegna Tota, A. Superti-Furga, A. Rossi
• Year: 2020
• Venue: International Journal of Molecular Sciences
• URL: https://www.semanticscholar.org/paper/e455f358a08f6e9fc09ef5f2d3751d11e9145e92
• DOI: 10.3390/ijms21082710
• PMID: 32295296
• PMCID: 7216085
• Citations: 25
• Influential citations: 1
• Summary: A panoramic view of skeletal dysplasias caused by mutations in genes encoding for transporters or enzymes involved in macromolecular sulfation is presented, allowing the development of targeted therapies aimed at alleviating, preventing, or modifying the disease progression.
• Evidence snippets:
• Snippet 1 (score: 0.491) > Over the last few years, there have been significant advances in the skeletal dysplasia field leading to the identification of the underlying genetic defects in more than 400 different skeletal disorders [15]. The above synopsis highlights the complexity of skeletal defects caused by mutations in genes encoding for enzymes and transporters involved in sulfate metabolism. Progress in this field has been allowed by next-generation genomic technologies, that are a first-line diagnostic resource. In this complex scenario, patient derived biopsies, cell cultures, and animal models are fundamental to investigate the pathogenesis and to analyze new aspects of the role of GAG in connective tissue biology. > Despite the great step forward in the identification of causative genes, genotype-phenotype correlations are lacking and we are still far from a comprehensive view of the disease molecular mechanisms. First, it is unclear how the tissue specificity and the redundancy of genes can determine the phenotype. Defects in PG sulfation mainly affect cartilage and bone, but other tissues can be involved as cardiac tissue in SEDCJD [82,84] or lymphoid tissue leading to tumour progression in OCBMD [91]. The involvement of different tissues and its implications on the disease phenotype should be carefully studied in the future. Moreover, mutations in different genes cause skeletal dysplasias with overlapping features that may be wrongly diagnosed as occurs in condrodysplasia with joint dislocation, gPAPP type, Catel-Manzke syndrome and Desbuquois dysplasia type 1. Nowadays we cannot provide a full explanation why some classes of sulfated PGs are more affected by enzyme deficiency than others. Even if the GAGs role depends on their physicochemical properties, it is difficult to molecularly dissect the function of sulfated GAGs when they interact in the complex ECM network. Lastly, the variability in the clinical phenotypes caused by mutations in the same gene suggests that also environmental and epigenetic factors might play a role. > A deep understanding of the molecular mechanisms of these disorders is crucial to ultimately pave the way for innovative therapies.

[11] TRPV4: A Physio and Pathophysiologically Significant Ion Channel

• Authors: T. Rosenbaum, Miguel Benítez-Angeles, Raúl Sánchez-Hernández, S. Morales-Lázaro, M. Hiriart et al.
• Year: 2020
• Venue: International Journal of Molecular Sciences
• URL: https://www.semanticscholar.org/paper/09943959f11255605b780fc692ef57a0cc9ef945
• DOI: 10.3390/ijms21113837
• PMID: 32481620
• PMCID: 7312103
• Citations: 105
• Influential citations: 3
• Summary: Several lines of evidence derived from animal models and even clinical trials in humans highlight TRPV4 as a therapeutic target and as a protein that will receive even more attention in the near future, as will be reviewed here.
• Evidence snippets:
• Snippet 1 (score: 0.484) > Certain diseases were previously thought to be distinct clinical phenotypes until it was discovered that there was a common underlying molecular basis: their association with the mutations and malfunction of TRPV4 (Figure 5). Presently, these disorders have been grouped into skeletal dysplasias (metatropic dysplasia, parastremmatic dysplasia, Maroteaux type spondyloepiphyseal dysplasia, Kozlowski type spondyloepiphyseal dysplasia (SMDK), autosomal dominant brachyolmia, familial digital arthropathy-brachydactyly), and into neuromuscular disorders (congenital distal spinal muscular atrophy, scapuloperoneal spinal muscular atrophy, Charcot-Marie-Tooth disease type 2C), which vary in severity. Skeletal dysplasias exhibit brachydactyly (shortness of fingers and toes), and depending on the severity of the disease, there is also short stature and spinal deformity, the pelvis, and long bones, which can also be affected, and sometimes the life span of the individuals is reduced. On the other hand, neuromuscular disorders present themselves with respiratory dysfunction, joint contractures, and progressive peripheral neuropathy [182]. > All of these diseases, which are grouped into two large categories (i.e., neuromuscular disease and skeletal dysplasia), encompass progressive degeneration of peripheral nerves or lack of establishment and development of the hard-skeletal tissues. > It had been previously shown that inactivation missense mutations in the PkdI (polycystic kidney disease) gene that encodes the polycystin-1 (PC1) membrane protein led to tardy intramembranous and endochondral bone formation in a mutant mice (Pkd1 mlBei ) strain [183]. A link between this discovery and the role of TRPV4 in the skeletal system was later made since it had been shown that PC1 activates TRPV4 through a G-protein coupled receptor (GPCR) mechanism [184].

[12] Non-Invasive Prenatal Screening for Down Syndrome: A Review of Mass-Spectrometry-Based Approaches

• Authors: Răzvan Lucian Jurca, I. Pralea, M. Iacobescu, I. Rus, C. Iuga et al.
• Year: 2025
• Venue: Life
• URL: https://www.semanticscholar.org/paper/77585fbeddaee796b0d9030dfccee9713f2d3e52
• DOI: 10.3390/life15050695
• PMID: 40430124
• PMCID: 12112985
• Citations: 1
• Summary: A comprehensive examination of the differentially expressed proteins (DEPs) and metabolites (DEMs) reported in the literature in T21 prenatal screening aims to guide future research in the field and foster the development of more advanced, less invasive prenatal screening techniques for T21.
• Evidence snippets:
• Snippet 1 (score: 0.484) > Additionally, CS and DS are commonly associated with atherosclerosis, nerve development and repair, inflammation, tumor growth, and metastasis [80]. Modifications of the enzymes involved in the biosynthesis of glycosaminoglycans are important in Ehlers-Danlos syndrome, joint dislocations, short stature, spondyloepiphyseal dysplasia with congenital joint dislocations, spondyloepimetaphyseal dysplasia with joint laxity type 1, congenital heart defects, and Temtamy preaxial brachydactyly syndrome. While congenital heart defects and joint laxity are common in T21 patients, the co-occurrence of T21 and Ehlers-Danlos syndrome is rare, and no established correlation exists between the two conditions [104]. > Pathways associated with diseases of hemostasis were predominantly observed in maternal plasma, along with pathways related to signal transduction mediated by growth factors and second messengers-specifically, oncogenic MAPK signaling. MAPKs are protein kinases that control intracellular processes, such as gene expression, metabolism, proliferation, differentiation, and apoptosis, as part of normal physiology, being mainly studied in the context of oncogenesis, tumor progression, and drug resistance [105]. MAPK pathways in T21 patients have been primarily studied to enhance antitumor treatment efficacy in patients with B cell acute lymphoblastic leukemia [106] or to assess MAPK activity in the brains of T21 and Alzheimer's disease patients [107]. > Table 2 summarizes the key molecular pathways implicated in Down syndrome (T21), emphasizing their normal biological functions and the observed or potential alterations in T21. While direct evidence for some pathways remains limited, numerous pathways-particularly those involved in signaling, immune functions, extracellular matrix organization, and metabolic processes-show promising associations with the clinical features of T21. Regarding the metabolomic pathways of significant differentially expressed metabolites (DEMs) in T21, brief discussions on this topic are included in the description of each metabolomic study outlined in the previous section.

[13] Spondyloepiphyseal dysplasia congenita

• Authors: Y. Glick
• Year: 2020
• Venue: Definitions
• URL: https://www.semanticscholar.org/paper/5c85234647b055c18b8374c50050dab900ffd7b3
• DOI: 10.1007/978-3-540-29676-8_6867
• Citations: 67
• Summary: People with spondyloepiphyseal dysplasia congenita have short stature from birth, with a very short trunk and neck and shortened limbs. Their hands and feet, however, are usually average-sized. Adult height ranges from 3 feet to just over 4 feet. Abnormal curvature of the spine (kyphoscoliosis and lordosis) becomes more severe during childhood. Instability of the spinal bones (vertebrae) in the neck may increase the risk of spinal cord damage. Other skeletal features include flattened vertebr...
• Evidence snippets:
• Snippet 1 (score: 0.481) > Spondyloepiphyseal dysplasia congenita

[14] A Roadmap to Gene Discoveries and Novel Therapies in Monogenic Low and High Bone Mass Disorders

• Authors: M. Formosa, D. Bergen, C. Gregson, A. Maurizi, A. Kämpe et al.
• Year: 2021
• Venue: Frontiers in Endocrinology
• URL: https://www.semanticscholar.org/paper/be13ff3ea01dc5719f2c63b2cbf5d9f77bafd659
• DOI: 10.3389/fendo.2021.709711
• PMID: 34539568
• PMCID: 8444146
• Citations: 21
• Summary: The monogenic forms of rare low and high rare bone Mass disorders known to date are described, a roadmap to unravel the genetic determinants of monogenic rare bone mass disorders is provided, using proper phenotyping and genotyping methods are provided, and different genetic validation approaches paving the way for future treatments are described.
• Evidence snippets:
• Snippet 1 (score: 0.476) > Skeletal development is regulated by numerous genetic factors that guide the growth, modeling and remodeling of skeletal structures starting in early fetal development and continuing throughout life. These processes are crucial for attainment of normal height, skeletal patterning, bone shape, and mobility, but also for maintenance of normal bone mass and fracture resistance. Defects in the involved genes result in a large and heterogeneous group of disorders, collectively called skeletal dysplasias, in which the primary features are confined to the skeleton. More than 460 different forms of skeletal dysplasia, most of them monogenic, have been recognized (1). They are estimated to affect approximately 1/5,000 children (2,3), and can have distinct clinical manifestations and course. Clinical outcomes range in severity from neonatal lethality to only mild growth retardation, deformity or fracture risk. Diagnosis is based on growth pattern and other clinical characteristics, skeletal imaging, bone density testing, biochemical diagnostics, and genetic tests. Although the genetic basis has been described and mutations in the responsible genes identified in a significant proportion of these conditions, for several distinct skeletal dysplasia phenotypes the genetic cause is still not known (1). > Within this large group of genetic skeletal disorders, monogenic disorders affecting bone mass comprise an expanding subgroup (1,4). This includes disorders with low bone mass and skeletal fragility, and disorders leading to increased bone mass, both commonly associated with extraskeletal complications (5,6). Due to significant variability in severity, diagnosis can be challenging. Importantly, the underlying molecular genetic mechanisms for these disorders remain inadequately explored and, in several entities, the causative genetic defect, and underlying cellular and molecular pathophysiology are still uncharacterized. > The various skeletal dysplasia delineated to date have provided important information about the molecular pathways governing skeletal health both in these conditions and in the general population, underscoring the significance of new gene discoveries not only for the individuals affected by the monogenic rare bone mass disorder, but also more widely to the musculoskeletal research field (7). Indeed, the large wealth of data generated from monogenic and polygenic bone mass disorders, frailty and other musculoskeletal traits, have led

[15] A novel type II collagen gene mutation in a family with spondyloepiphyseal dysplasia and extensive intrafamilial phenotypic diversity

• Authors: Y. Nakashima, Y. Sakamoto, G. Nishimura, S. Ikegawa, Y. Iwamoto
• Year: 2016
• Venue: Human Genome Variation
• URL: https://www.semanticscholar.org/paper/319ca8291900c74c780bf0a97de3f32ec8ef6f61
• DOI: 10.1038/hgv.2016.7
• PMID: 27274858
• PMCID: 4871930
• Citations: 7
• Summary: A family with spondyloepiphyseal dysplasia caused by a novel type II collagen gene (COL2A1) mutation and the family’s phenotypic diversity was described, finding Phenotypes were diverse even among individuals with the same mutation and within the same family.
• Evidence snippets:
• Snippet 1 (score: 0.458) > More than 400 COL2A1 mutations have been reported in the Human Gene Mutation Database (https://portal.biobase-international.com/hgmd/), and these mutations result in a diverse phenotypic spectrum that predominantly affects cartilage and bone. 3,4 On the basis of clinical findings, type II collagenopathies are divided into several categories, including spondyloepiphyseal dysplasia (SED) spectrum, Stickler dysplasia type I and Kniest dysplasia. 5,6 The SED spectrum is further divided into several phenotypes. 3 Achondrogenesis type II and hypochondrogenesis are lethal and at the severe end of this spectrum. SED congenita is characterized by short stature with a short trunk and coxa vara. SED tarda indicates late-onset SED. The distinction among the SED spectrum phenotypes is mainly based on clinical features; however, considerable phenotypic diversity often hampers proper classification even with the same mutation. 5 In the present study, we describe a Japanese family with SED caused by a novel COL2A1 mutation. This mutation predominantly affected the hip joint and spine of the affected individuals in this family. In addition, extensive intrafamilial phenotypic diversity was observed. > This study was approved by the local Institutional Review Board, and informed consent was obtained from all participants. > The index case (case 4) was a 50-year-old female with bilateral hip pain during her initial examination. Plain radiographs showed joint space narrowing without acetabular dysplasia and atlantoaxial subluxation and platyspondyly in her thoracolumbar spine (Figure 1a-c). She was diagnosed with SED. Her family members also exhibited below average height, and/or spine and joint symptoms. Their pedigree is shown in Figure 2a. The patient's skeletal problems seemed to be an inherited autosomal dominant trait; thus, we performed clinical and molecular surveys on seven affected members (cases 1-4 and 6-8) and one normal member (case 5) of her family. Table 1 is a summary of clinical and radiographic findings from the family. The stature of affected members ranged from extremely short to

[16] Galactosialidosis: A Report of Three Cases Diagnosed With a Founder Genetic Mutation in the Bahraini Population

• Authors: Z. Alsahlawi, Zahraa J. Alhadi, E. Abdulla, Sara H Ebrahim, Manal M Alshehab et al.
• Year: 2025
• Venue: Cureus
• URL: https://www.semanticscholar.org/paper/9e8abc846c9856fa0473c83ff0ca8dc2d21aed56
• DOI: 10.7759/cureus.77750
• PMID: 39981487
• PMCID: 11840274
• Citations: 1
• Summary: Three newly diagnosed cases of late-infantile GS in Bahraini patients, all sharing the same previously reported homozygous mutation in the CTSA gene are presented, reflecting a founder effect in the Bahraini population.
• Evidence snippets:
• Snippet 1 (score: 0.447) > Chest X-ray was normal, and lumbosacral spine imaging was suggestive of spondyloepiphyseal dysplasia congenita. A bone mineral density scan of the hands showed normal texture and density for her age. > Two years later, a magnetic resonance imaging (MRI) of the pelvis revealed bilateral significant flattening of the femoral capital epiphysis, which was symmetrical with dysplastic features of the hip. While these findings simulated Perthes disease, bone dysplasia and the possibility of spondyloepiphyseal dysplasia with mucopolysaccharidosis were considered more likely. > Laboratory investigations, including hormonal assays, were normal. A screening test for urinary glycosaminoglycans (GAGs) was sent to Frankfurt, Germany, with results showing a normal GAG pattern, thus excluding all types of mucopolysaccharidosis except MPS type IV (Morquio syndrome), which could not definitely be excluded based on clinical and radiological findings. > Further investigations, including ophthalmology and cardiology reviews, were suggested but not completed, as the patient lost follow-up after the age of 15 years. Additionally, scanogram images of the lower Based on the clinical presentation, laboratory results, skeletal findings, and a positive mutation in her younger brother for GS, the patient was called to attend the metabolic and genetic clinic. At the age of 28 years, coinciding with her brother's diagnosis of GS in the same year, the diagnosis of GS for her was confirmed through targeted mutation analysis using polymerase chain reaction. This genetic testing identified a homozygous mutation in the CTSA gene (c.607C>A, p.Pro203Thr). > The patient is currently stable, with no significant complications other than skeletal deformities and difficulty walking long distances, accompanied by back pain. Genetic counseling was given to the family about the risk of recurrence, other siblings have not been tested for the familial variant as they clearly do not have any symptoms related to the disease.

[17] Specific heterozygous variants in MGP lead to endoplasmic reticulum stress and cause spondyloepiphyseal dysplasia

• Authors: O. Gourgas, G. Lemire, Alison J. Eaton, Sultanah Alshahrani, A. Duker et al.
• Year: 2023
• Venue: Nature Communications
• URL: https://www.semanticscholar.org/paper/6f3fb0c824daec40f303c94dede4c9a8f28e13ad
• DOI: 10.1038/s41467-023-41651-6
• PMID: 37923733
• PMCID: 10624854
• Citations: 9
• Summary: It is reported that heterozygous missense variants affecting one particular cysteine residue of MGP can cause a clinically distinct, dominant disorder, likely via impaired signal peptide processing leading to cellular stress and apoptosis.
• Evidence snippets:
• Snippet 1 (score: 0.447) > Exome sequencing combined with a one-sided matchmaking strategy resulted in the identification of four individuals from two unrelated families with a heterozygous variant in MGP affecting the same highly conserved cysteine (Cys 19) residue. These individuals presented with a strikingly overlapping spondyloepiphyseal dysplasia phenotype, which was distinct from that of individuals with KS caused by biallelic loss-of-function variants in MGP 11 . Platyspondyly and progressive epiphyseal degeneration were significant in the four affected individuals in this report which were not described in patients with KS. Also, pulmonary artery stenosis, arterial calcification, hearing loss, and developmental delay are common clinical features in KS and were not present in the individuals from this cohort 8,[18][19][20] . Nonetheless, there were a few notable phenotypic similarities between the current cohort of affected individuals and KS patients. Radiographs of the hands of affected individuals demonstrated brachytelephalangism of the lesser digits, which is seen in KS. Midface retrusion is also a clinical feature observed in individuals with KS 11,21 and was seen in our cohort, especially in Individual 4 carrying the 56G>A variant. In addition, Individual 4 did appear to have premature calcification of the cricoid cartilage, albeit not as significant as the vast tracheal ring calcifications seen in KS. Short stature has also been reported in individuals with KS 10,18 . Despite these similarities, the defining features of the affected individuals with heterozygous 56G>T or 56G>A variants in MGP, the vertebral and epiphyseal anomalies, make the condition clinically distinct from KS. We suggest naming this condition Spondyloepiphyseal dysplasia (SED), MGP type. Reporting of additional affected individuals in future will improve the clinical delineation of SED, MGP type. > The identification of novel MGP variants affecting the same cysteine residue in individuals with a previously unreported skeletal disorder and their autosomal dominant mode of inheritance demanded a thorough investigation into the underlying cell and molecular mechanisms.

[18] Signaling Pathways in Bone Development and Their Related Skeletal Dysplasia

• Authors: Alessandra Guasto, V. Cormier-Daire
• Year: 2021
• Venue: International Journal of Molecular Sciences
• URL: https://www.semanticscholar.org/paper/c5466b45e1a7e5aa8e7ad05c7d9287a9e84e9262
• DOI: 10.3390/ijms22094321
• PMID: 33919228
• PMCID: 8122623
• Citations: 51
• Summary: The principal signaling pathways involved in bone development and their associated skeletal dysplasia are reviewed and genotype–phenotype correlations have helped to elucidate their role in skeletogenesis.
• Evidence snippets:
• Snippet 1 (score: 0.445) > In this review, we discussed the main signaling pathways involved in bone development and how mutations in their components have been associated with SD. It is important to highlight that even if the signaling pathways have been discussed independently, there is a complex cross-talk among them at multiple levels. This, in association with the evidence that the mutation consequences depend on the specificity of the mutations and on their temporal and spatial mode of action, makes more difficult the understanding of the physiopathological mechanisms of these diseases. Moreover, these signaling pathways can be secondarily affected by alterations in other cellular processes, such as extracellular matrix regulation or metabolic processing. Indeed, several skeletal dysplasia, that we decided to omit in this review, have been associated with mutations in these processes. Fortunately, in the last decade, the development of new technologies, like whole exome and genome sequencing has accelerated the identification of skeletal dysplasia-causing mutations. On the other hand, the development of CRISPR-Cas9 technology and of several mouse models is helping the deciphering of the physiopathological mechanisms. Advanced genetic testing is also helping the diagnosis of skeletal dysplasia. The diagnosis and management of these pathologies have long been based on clinical feature and skeletal imaging. Today, these key techniques are increasingly combined with the genetic testing in order to obtain a more accurate and early diagnosis of SD. It also aids in prognosis and in counselling families regarding genetic recurrence risk and preconceptional reproductive planning [212][213][214]. These continuous discoveries will help to expand the genotype-phenotype correlation of SD and to develop new therapeutic strategies. Nowadays, few treatments are available for SD, but several clinical trials are ongoing to validate new drugs targeting specifically these pathways in achondroplasia or FOP for example, and highlighting the importance of multidisciplinary cross talks (from bed to bench side) [215].

Notes

• This provider combines search_papers_by_relevance with snippet_search.
• No synthesis or second-stage model call is performed.

Disorder

• Name: Spondyloepiphyseal Dysplasia Congenita
• Category: Mendelian
• Existing deep-research providers: cyberian-codex, perplexity
• Existing evidence reference count in YAML: 16

Key Pathophysiology Nodes

• Type II Collagen Dysfunction
• Vitreous Collagen Abnormality
• Deep research literature mapping

Citation Inventory (for evidence mapping)

• DOI:10.1002/dvdy.24131
• DOI:10.1002/mgg3.1139
• DOI:10.1073/pnas.1302703111
• DOI:10.3389/fgene.2022.960504
• PMID:10743764
• PMID:11878179
• PMID:1971141
• PMID:31824186
• PMID:3977716
• PMID:6499247
• PMID:6807266

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

• Disease Name: Spondyloepiphyseal Dysplasia Congenita
• MONDO ID: (if available)
• Category: Mendelian

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Spondyloepiphyseal Dysplasia Congenita. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

• What are the primary pathophysiological mechanisms?
• What molecular pathways are dysregulated?
• What cellular processes are affected?

2. Key Molecular Players

• Genes/Proteins: Which genes are causally involved or implicated?
• Chemical Entities: What metabolites, drugs, or small molecules are relevant?
• Cell Types: Which cell types are primarily affected?
• Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

• What biological processes (GO terms) are disrupted?
• Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

• Where in the cell do key processes occur?
• Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

• What is the sequence of events from initial trigger to clinical manifestation?
• Are there distinct stages or phases?

6. Phenotypic Manifestations

• What are the key clinical phenotypes?
• How do they relate to the underlying mechanisms?

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic claims
• Prioritize recent reviews and landmark papers
• Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Comprehensive Research Report: Pathophysiology of Spondyloepiphyseal Dysplasia Congenita (SEDC)

Disease overview and key definitions

Spondyloepiphyseal dysplasia congenita (SEDC) is a Mendelian (typically autosomal dominant) skeletal dysplasia within the type II collagenopathy spectrum caused by pathogenic variants in COL2A1 (collagen type II alpha 1 chain). It is characterized by disproportionate short-trunk short stature with platyspondyly and epiphyseal dysplasia and has frequent extraskeletal manifestations due to type II collagen expression in the vitreous and inner ear (ocular and hearing involvement). (zhan2025clinicalfeaturesof pages 2-2, marchionni2023clinicalandfunctional pages 1-2)

Epidemiology/statistics (selected): * A review focused on COL2A1/SEDC reports SEDC prevalence ~3.4 per 1,000,000. (nenna2019col2a1genemutations pages 2-3) * In a published SEDC cohort summary cited by a 2022 SEDC series: 86% short stature, >50% underwent orthopedic surgery, 45% myopia, 37% hearing loss. (akahiraazuma2022novelcol2a1variants pages 2-3) * Additional complication rates reported in the COL2A1/SEDC review include retinal detachment ~12% and sensorineural hearing loss ~25–30% of adults. (nenna2019col2a1genemutations pages 2-3)

1) Core pathophysiology (current understanding)

SEDC is primarily a disorder of type II collagen biosynthesis, folding/quality control, secretion, and extracellular matrix (ECM) assembly in cartilage. The unifying mechanistic theme across model systems is that many COL2A1 variants (especially glycine substitutions in the triple helix, or certain C-propeptide variants) produce misfolded procollagen-II, which then: 1. Folds slowly / aberrantly and becomes hypermodified, 2. Accumulates intracellularly (often in the rough ER) causing ER dilation, 3. Leads to either: * canonical ER stress / UPR activation with apoptosis in some settings (strongly supported in a Col2a1 p.Gly1170Ser knock-in mouse), or * ER storage with minimal transcriptional UPR activation in other settings (supported in a 2024 human iPSC-derived cartilage model). 4. Results in decreased secretion and defective extracellular collagen fibril network, producing a sparse/disorganized cartilage ECM. 5. Disrupts growth plate architecture and chondrocyte differentiation (including hypertrophy), impairing endochondral ossification and leading to short-trunk dwarfism and epiphyseal/spinal malformations. (liang2014endoplasmicreticulumstressunfolding pages 1-3, esapa2012amousemodel pages 1-2, yammine2023erprocollagenstorage pages 9-12)

Direct mechanistic quote-level evidence: In a Col2a1 p.Gly1170Ser knock-in mouse model, mutant procollagen “was largely synthesized and retained in dilated endoplasmic reticulum” and this retention could “activate a signaling network of the unfolded protein response (UPR)” and, if unresolved, “apoptosis was initiated”; importantly, apoptosis “occurred prior to hypertrophy,” preventing formation of a hypertrophic zone and causing chondrodysplasia. (liang2014endoplasmicreticulumstressunfolding pages 1-3)

2) Dysregulated molecular pathways

A. Collagen folding/processing and ER proteostasis

A 2024 human iPSC-derived cartilage model of COL2A1 p.Gly1170Ser provides quantitative evidence of ER retention and hypermodification: * Intracellular retention by blinded IHC scoring: 64% of heterozygous cells retained procollagen-II vs 34% WT; >80% retention in homozygotes. (yammine2023erprocollagenstorage pages 9-12) * Triple-helix assembly burden: in heterozygotes, >85% of trimers contained at least one mutant chain. (yammine2023erprocollagenstorage pages 9-12) * ER localization supported by co-localization with calreticulin and ER dilation by TEM. (yammine2023erprocollagenstorage pages 9-12)

This study frames the defect as an “ER storage disorder”: mutant procollagen-II “accumulates intracellularly, consistent with an endoplasmic reticulum (ER) storage disorder,” and is “notably slow to fold and secrete.” (yammine2023erprocollagenstorage pages 1-5)

B. Unfolded Protein Response (UPR) branches (PERK/ATF4/CHOP, IRE1/XBP1, ATF6)

Model-dependent UPR engagement is a key nuance in current understanding.

In vivo mouse (UPR+apoptosis phenotype): The Col2a1 p.Gly1170Ser knock-in mouse directly assayed canonical UPR components by qRT-PCR (Chop, Total-Xbp1, Spliced-Xbp1, Grp78/BiP, ATF4, ATF6), consistent with engagement of PERK/ATF4/CHOP, IRE1/XBP1, and ATF6 branches. (liang2014endoplasmicreticulumstressunfolding pages 5-9)

Human iPSC cartilage model (limited transcriptional UPR): In the 2024 iPSC cartilage model, despite prominent ER retention and ER dilation, transcriptome/GSEA analyses showed no detectable UPR induction in clinically relevant heterozygotes (and only modest changes in homozygotes at an early time point). (yammine2023erprocollagenstorage pages 9-12)

This group explicitly states that ER accumulation was not accompanied by “any substantive UPR” and noted an “absence of the type of chronic activation of the PERK arm of the UPR that can induce apoptosis over time.” (yammine2023erprocollagenstorage pages 15-18)

Interpretation: The field is converging on the idea that misfolded collagen retention is necessary but not sufficient for a canonical UPR signature; the collagen triple helix may be unusually “UPR-evasive” compared with globular misfolded proteins, leading to substantial ER retention with muted UPR depending on allele dosage, cell state, and model system. (yammine2023erprocollagenstorage pages 9-12, yammine2023erprocollagenstorage pages 15-18)

C. Apoptosis and growth plate disruption

In the Col2a1 p.Gly1170Ser knock-in mouse, chondrocyte apoptosis is a central causal event and occurs before hypertrophic differentiation, thereby collapsing the hypertrophic zone and impairing endochondral ossification. (liang2014endoplasmicreticulumstressunfolding pages 1-3)

Image-based evidence from the same study shows: * Dilated rough ER on TEM in mutant proliferating-zone chondrocytes. * Intracellular retention of mutant procollagen-II co-localizing with GRP78 (ER marker). * Upregulation of UPR/ER-stress genes. * Increased apoptosis by cleaved caspase-3 staining and TUNEL positivity. (liang2014endoplasmicreticulumstressunfolding media a802b0c3, liang2014endoplasmicreticulumstressunfolding media 7e048216, liang2014endoplasmicreticulumstressunfolding media 4409704f, liang2014endoplasmicreticulumstressunfolding media 919d3da4)

In contrast, the 2024 iPSC cartilage model did not detect increased apoptosis (TUNEL) in either heterozygous or homozygous chondronoids, despite ER retention—again emphasizing context dependence. (yammine2023erprocollagenstorage pages 12-15)

D. Extracellular matrix (ECM) fibrillogenesis defects

Multiple sources support defective extracellular collagen network formation: * The 2024 iPSC cartilage model described collagen fibrils as “generally shorter, yielding a very sparse network,” with “intracellular retention of collagen-II,” and “dilated ER.” (yammine2024erprocollagenstoragea pages 83-88) * A Col2a1 C-propeptide (Ser1386Pro) mouse model showed reduced cartilage type II collagen staining and EM evidence of fewer/less elaborate collagen fibrils plus enlarged ER vacuoles containing inclusions—supporting defective fibrillogenesis coupled to intracellular trafficking/processing defects. (esapa2012amousemodel pages 1-2)

3) Key molecular players

Genes / proteins

Causal gene * COL2A1 (HGNC:2200) — encodes the α1(II) chain of type II procollagen (a homotrimer), the major fibrillar collagen of hyaline cartilage; produced by proliferating chondrocytes. (marchionni2023clinicalandfunctional pages 1-2)

Core ER stress/UPR markers and regulators observed/assayed in SEDC models * HSPA5/GRP78/BiP (ER chaperone; used as ER marker and UPR readout). (liang2014endoplasmicreticulumstressunfolding pages 5-9, liang2014endoplasmicreticulumstressunfolding media a802b0c3) * XBP1 (spliced Xbp1) (IRE1 branch output). (liang2014endoplasmicreticulumstressunfolding pages 5-9) * ATF4 (PERK branch output). (liang2014endoplasmicreticulumstressunfolding pages 5-9) * ATF6 (ATF6 branch). (liang2014endoplasmicreticulumstressunfolding pages 5-9) * DDIT3/CHOP (pro-apoptotic UPR mediator). (liang2014endoplasmicreticulumstressunfolding pages 5-9)

Proteostasis/collagen-modifying factors enriched for interaction with slow-folding mutant procollagen-II (human iPSC model) * PLOD2, P4HB, P3H1, FKBP10, PPIB, plus chaperones CALR (calreticulin) and SERPINH1 (HSP47) consistent with slow folding/hypermodification and ER retention. (yammine2023erprocollagenstorage pages 12-15)

Apoptosis readouts (mouse model evidence) * Cleaved caspase-3 and TUNEL positivity in growth plate chondrocytes. (liang2014endoplasmicreticulumstressunfolding media a802b0c3, liang2014endoplasmicreticulumstressunfolding media 7e048216)

Chemical entities (metabolites/drugs/small molecules)

No disease-modifying pharmacologic therapy is established for SEDC in the provided mechanistic evidence set. However, the iPSC cartilage model explicitly positions itself as enabling “rapid testing of therapeutic strategies to restore proteostasis in the collagenopathies,” implying chemical chaperones/proteostasis modulators as plausible candidates for future work. (yammine2023erprocollagenstorage pages 1-5)

Cell types (primary)

• Chondrocytes (including growth plate chondrocytes; proliferative and hypertrophic zones). (nenna2019col2a1genemutations pages 2-3, esapa2012amousemodel pages 1-2)

Anatomical locations / tissues

• Hyaline cartilage and growth plate cartilage (primary lesion site). (morales2025theuseof pages 38-42, esapa2012amousemodel pages 1-2)
• Vertebrae (platyspondyly) and epiphyses/proximal long bones (epiphyseal dysplasia). (zhan2025clinicalfeaturesof pages 2-2, akahiraazuma2022novelcol2a1variants pages 2-3)
• Vitreous/retina (myopia/retinal detachment risk) and inner ear (hearing impairment). (nenna2019col2a1genemutations pages 2-3, zhan2025clinicalfeaturesof pages 2-2)

4) Biological processes disrupted (GO-oriented)

Based on mechanistic evidence in mouse and human cartilage models, disrupted processes include: * Protein folding and quality control in the endoplasmic reticulum (misfolded procollagen retention; ER dilation). (liang2014endoplasmicreticulumstressunfolding pages 1-3, yammine2023erprocollagenstorage pages 9-12) * Unfolded protein response (UPR) (PERK/ATF4/CHOP; IRE1/XBP1; ATF6) — robust in some in vivo settings, minimal in others. (liang2014endoplasmicreticulumstressunfolding pages 5-9, yammine2023erprocollagenstorage pages 9-12) * ER-associated stress response / ER lumen homeostasis (evidenced by GRP78 localization and ER dilation). (liang2014endoplasmicreticulumstressunfolding media a802b0c3, yammine2023erprocollagenstorage pages 9-12) * Apoptotic process (cleaved caspase-3/TUNEL positivity in growth plate). (liang2014endoplasmicreticulumstressunfolding media a802b0c3, liang2014endoplasmicreticulumstressunfolding media 7e048216) * Collagen fibril organization / extracellular matrix organization (sparse, abnormal collagen fibrillar network; reduced secretion). (yammine2024erprocollagenstoragea pages 83-88, esapa2012amousemodel pages 1-2) * Chondrocyte proliferation and differentiation (including hypertrophic differentiation) (reduced proliferation; hypertrophic zone failure in mouse). (liang2014endoplasmicreticulumstressunfolding pages 5-9, liang2014endoplasmicreticulumstressunfolding pages 1-3)

5) Cellular components (where processes occur)

• Rough endoplasmic reticulum / ER lumen — site of procollagen synthesis, folding, retention, ER dilation, and UPR sensing. (liang2014endoplasmicreticulumstressunfolding media a802b0c3, yammine2023erprocollagenstorage pages 9-12)
• Golgi apparatus / secretory pathway vesicles — implicated in abnormal trafficking/processing of mutant collagen. (marchionni2023clinicalandfunctional pages 1-2)
• Extracellular space / cartilage extracellular matrix — deficient/sparse collagen network and abnormal fibrils. (yammine2024erprocollagenstoragea pages 83-88, esapa2012amousemodel pages 1-2)

6) Disease progression model (sequence of events)

A mechanistically supported sequence integrating mouse and human iPSC evidence is: 1. Primary trigger: pathogenic COL2A1 variant (commonly glycine substitution in triple helix; or C-propeptide variant). (marchionni2023clinicalandfunctional pages 1-2, esapa2012amousemodel pages 1-2) 2. Molecular defect: slow folding/misfolding of procollagen-II → hypermodification, impaired trimer maturation. (yammine2023erprocollagenstorage pages 9-12) 3. Cellular defect: ER retention/accumulation → ER dilation; variable engagement of canonical UPR transcription depending on context/dose. (yammine2023erprocollagenstorage pages 9-12, liang2014endoplasmicreticulumstressunfolding pages 5-9) 4. Downstream cellular outcome (context-dependent): * In severe settings: UPR activation (CHOP/XBP1/ATF4/ATF6) → apoptosis (cleaved caspase-3, TUNEL) → loss of hypertrophic zone and disrupted growth plate. (liang2014endoplasmicreticulumstressunfolding pages 1-3, liang2014endoplasmicreticulumstressunfolding media a802b0c3) * In other settings: ER storage disorder with adaptive remodeling and minimal UPR signature, but persistent matrix deficiency. (yammine2023erprocollagenstorage pages 9-12, yammine2023erprocollagenstorage pages 15-18) 5. Tissue outcome: sparse/abnormal cartilage ECM, growth plate disorganization → abnormal endochondral ossification. (esapa2012amousemodel pages 1-2, yammine2024erprocollagenstoragea pages 83-88) 6. Clinical outcome: disproportionate short-trunk short stature, vertebral flattening, epiphyseal dysplasia; progressive joint disease/early osteoarthritis; ocular and hearing complications. (akahiraazuma2022novelcol2a1variants pages 2-3, nenna2019col2a1genemutations pages 2-3)

7) Phenotypic manifestations (HP-oriented)

Key phenotypes and mechanistic links: * Disproportionate short stature / short trunk arises from growth plate dysfunction and impaired endochondral ossification due to deficient collagen II ECM and (in some models) growth plate chondrocyte apoptosis. (liang2014endoplasmicreticulumstressunfolding pages 1-3, zhan2025clinicalfeaturesof pages 2-2) * Platyspondyly and epiphyseal dysplasia reflect abnormal cartilage template formation in vertebrae and proximal epiphyses. (zhan2025clinicalfeaturesof pages 2-2, akahiraazuma2022novelcol2a1variants pages 2-3) * Early degenerative joint disease / osteoarthritis plausibly reflects both developmental cartilage defects and ongoing matrix fragility; supported by mouse models with secondary OA. (esapa2012amousemodel pages 1-2) * Myopia/retinal detachment and hearing impairment track with type II collagen roles in vitreous and inner ear structures; frequencies reported above. (akahiraazuma2022novelcol2a1variants pages 2-3, nenna2019col2a1genemutations pages 2-3)

8) Recent developments and latest research (prioritizing 2023–2024)

2024 (preprint): Human iPSC-derived cartilage model reframing ER stress expectations. A 2024 iPSC-derived cartilage study of COL2A1 p.Gly1170Ser provides a quantitatively supported concept that type II collagen misfolding can create an ER procollagen storage defect without a coupled canonical UPR, challenging a simplistic “misfolding always → UPR → apoptosis” model. The study quantifies intracellular retention (64% vs 34% WT) and shows ER dilation and a sparse collagen network but minimal UPR transcriptional induction in heterozygotes and no increased apoptosis by TUNEL. (yammine2023erprocollagenstorage pages 9-12, yammine2023erprocollagenstorage pages 12-15)

2023: Cellular functional characterization in patients/variants. A 2023 functional case-based analysis of a COL2A1 glycine substitution links glycine replacements to disrupted triple helix integrity and reports intracellular accumulation/secretory pathway alterations and ECM disorganization (e.g., fibronectin network disruption) consistent with defective matrix assembly in type II collagenopathies. (marchionni2023clinicalandfunctional pages 1-2)

9) Current applications and real-world implementations

• Molecular diagnosis in clinical practice: NGS panels/WES plus confirmatory Sanger sequencing are routinely used for COL2A1 variant identification; accurate diagnosis is emphasized for early monitoring of extraskeletal complications (ocular/hearing/cervical instability). (akahiraazuma2022novelcol2a1variants pages 1-2)
• Model systems for therapeutic development: iPSC-derived cartilage/chondronoid platforms are positioned as translational tools for mechanistic study and therapeutic screening of proteostasis-restoring interventions in collagenopathies. (yammine2023erprocollagenstorage pages 1-5)

10) Expert opinion / analysis (authoritative synthesis)

Across mechanistic sources, there is consensus that cartilage ECM deficiency driven by mutant collagen II proteostasis and assembly defects is central to SEDC. The key expert-level nuance from recent iPSC work is that the presence/absence of canonical UPR signatures may vary by genotype dosage and model, and thus UPR readouts are not universally reliable proxies for collagen II misfolding burden; nonetheless, ER retention and ECM deficiency remain consistent cellular pathologies. (yammine2023erprocollagenstorage pages 9-12, liang2014endoplasmicreticulumstressunfolding pages 1-3)

Knowledge-base-ready structured annotations

MONDO / disease identifiers

• MONDO ID was not available in the retrieved evidence set.

Gene / protein annotations (HGNC)

• COL2A1 (HGNC:2200) — causal gene for SEDC. (akahiraazuma2022novelcol2a1variants pages 1-2)

Key pathways / processes (GO candidates; evidence-linked)

• Protein folding in endoplasmic reticulum (misfolded procollagen retained in dilated ER). (liang2014endoplasmicreticulumstressunfolding pages 1-3, yammine2023erprocollagenstorage pages 9-12)
• Unfolded protein response (Chop/Xbp1/Grp78/ATF4/ATF6 assayed and upregulated in mouse). (liang2014endoplasmicreticulumstressunfolding pages 5-9)
• Apoptotic process (cleaved caspase-3/TUNEL in mouse growth plate). (liang2014endoplasmicreticulumstressunfolding media a802b0c3, liang2014endoplasmicreticulumstressunfolding media 7e048216)
• Collagen fibril organization / extracellular matrix organization (sparse network, abnormal fibrils, reduced secretion). (yammine2024erprocollagenstoragea pages 83-88, esapa2012amousemodel pages 1-2)
• Chondrocyte proliferation and hypertrophic differentiation (reduced proliferation; loss of hypertrophic zone in severe mouse model). (liang2014endoplasmicreticulumstressunfolding pages 5-9, liang2014endoplasmicreticulumstressunfolding pages 1-3)

Cellular components (GO-CC candidates)

• Rough endoplasmic reticulum / ER lumen (dilated ER with retained procollagen). (liang2014endoplasmicreticulumstressunfolding media a802b0c3, yammine2023erprocollagenstorage pages 9-12)
• Golgi apparatus / secretory vesicles (trafficking/processing changes for mutant collagen). (marchionni2023clinicalandfunctional pages 1-2)
• Extracellular matrix / extracellular space (deficient collagen network). (yammine2024erprocollagenstoragea pages 83-88)

Cell type involvement (CL candidates)

• Chondrocyte (including growth plate chondrocytes). (esapa2012amousemodel pages 1-2, nenna2019col2a1genemutations pages 2-3)

Anatomical locations (UBERON candidates)

• Hyaline cartilage and growth plate cartilage. (morales2025theuseof pages 38-42, esapa2012amousemodel pages 1-2)
• Vertebrae and epiphyses of long bones. (akahiraazuma2022novelcol2a1variants pages 2-3, zhan2025clinicalfeaturesof pages 2-2)
• Vitreous body/retina and inner ear. (nenna2019col2a1genemutations pages 2-3, zhan2025clinicalfeaturesof pages 2-2)

Phenotype associations (HP candidates)

• Disproportionate short stature / short trunk, platyspondyly, epiphyseal dysplasia, hip dysplasia/coxa vara, early osteoarthritis, myopia, retinal detachment, sensorineural hearing loss, cleft palate/Pierre Robin sequence. (akahiraazuma2022novelcol2a1variants pages 2-3, nenna2019col2a1genemutations pages 2-3, marchionni2023clinicalandfunctional pages 1-2)

Chemical entities (CHEBI candidates)

• No specific disease-modifying small molecules were identified in the retrieved mechanistic evidence; proteostasis-targeting strategies are proposed conceptually for testing in iPSC models. (yammine2023erprocollagenstorage pages 1-5)

Evidence items with PMIDs (where available)

• Liang et al., PLoS ONE (Jan 2014) “Endoplasmic Reticulum Stress-Unfolding Protein Response-Apoptosis Cascade Causes Chondrodysplasia in a col2a1 p.Gly1170Ser Mutated Mouse Model.” DOI: https://doi.org/10.1371/journal.pone.0086894 (PMID not provided in retrieved text). (liang2014endoplasmicreticulumstressunfolding pages 1-3, liang2014endoplasmicreticulumstressunfolding pages 5-9)
• Esapa et al., J Bone Miner Res (Feb 2012) “A mouse model for spondyloepiphyseal dysplasia congenita with secondary osteoarthritis due to a Col2a1 mutation.” DOI: https://doi.org/10.1002/jbmr.547 (PMID not provided in retrieved text). (esapa2012amousemodel pages 1-2)
• Akahira-Azuma et al., Human Genome Variation (May 2022) DOI: https://doi.org/10.1038/s41439-022-00193-x (PMID not provided in retrieved text). (akahiraazuma2022novelcol2a1variants pages 2-3)
• Marchionni et al., Bone Reports (Dec 2023) DOI: https://doi.org/10.1016/j.bonr.2023.101728 (PMID not provided in retrieved text). (marchionni2023clinicalandfunctional pages 1-2)
• Yammine et al., bioRxiv (Oct 2024; preprint originally posted 2023-10-19) “ER procollagen storage defect without coupled unfolded protein response drives precocious arthritis.” DOI: https://doi.org/10.1101/2023.10.19.562780 (preprint; no PMID). (yammine2023erprocollagenstorage pages 9-12, yammine2023erprocollagenstorage pages 12-15)
• Nenna et al., Application of Clinical Genetics (Dec 2019) DOI: https://doi.org/10.2147/tacg.s197205 (PMID not provided in retrieved text). (nenna2019col2a1genemutations pages 2-3)

Notes on PMID availability

PMIDs were not present in the retrieved text snippets for several articles (including key mechanistic mouse studies). The DOIs and publication metadata above provide stable identifiers; PMIDs can be programmatically resolved from DOIs if needed.

References

1. (zhan2025clinicalfeaturesof pages 2-2): Shumin Zhan, Qin He, Jinna Yuan, Xiaoqin Xu, Ke Huang, Guanping Dong, Junfen Fu, Dingwen Wu, and Wei Wu. Clinical features of seven col2a1 variations in chinese children with type ii collagen disorders. Acta Paediatrica (Oslo, Norway : 1992), 114:1720-1730, Feb 2025. URL: https://doi.org/10.1111/apa.70029, doi:10.1111/apa.70029. This article has 5 citations.

2. (marchionni2023clinicalandfunctional pages 1-2): Enrica Marchionni, Maria Rosaria D'Apice, Viviana Lupo, Giovanna Lattanzi, Elisabetta Mattioli, Gina Lisignoli, Elena Gabusi, Gerardo Pepe, Manuela Helmer Citterich, Elena Campione, Anna Maria Nardone, Paola Spitalieri, Noemi Pucci, Dario Cocciadiferro, Eliseo Picchi, Francesco Garaci, Antonio Novelli, and Giuseppe Novelli. Clinical and functional characterization of col2a1 p.gly444ser variant: from a fetal phenotype to a previously undisclosed postnatal phenotype. Bone Reports, 19:101728, Dec 2023. URL: https://doi.org/10.1016/j.bonr.2023.101728, doi:10.1016/j.bonr.2023.101728. This article has 1 citations and is from a peer-reviewed journal.

3. (nenna2019col2a1genemutations pages 2-3): Raffaella Nenna, Arianna Turchetti, Gerarda Mastrogiorgio, and Fabio Midulla. Col2a1 gene mutations: mechanisms of spondyloepiphyseal dysplasia congenita. The Application of Clinical Genetics, 12:235-238, Dec 2019. URL: https://doi.org/10.2147/tacg.s197205, doi:10.2147/tacg.s197205. This article has 51 citations.

4. (akahiraazuma2022novelcol2a1variants pages 2-3): Moe Akahira-Azuma, Yumi Enomoto, Naoyuki Nakamura, Takayuki Yokoi, Mari Minatogawa, Noriaki Harada, Yoshinori Tsurusaki, and Kenji Kurosawa. Novel col2a1 variants in japanese patients with spondyloepiphyseal dysplasia congenita. Human Genome Variation, May 2022. URL: https://doi.org/10.1038/s41439-022-00193-x, doi:10.1038/s41439-022-00193-x. This article has 4 citations.

5. (liang2014endoplasmicreticulumstressunfolding pages 1-3): Guo-yan Liang, Chengjie Lian, Di Huang, Wenjie Gao, Anjing Liang, Yan Peng, Wei Ye, Zizhao Wu, Peiqiang Su, and Dongsheng Huang. Endoplasmic reticulum stress-unfolding protein response-apoptosis cascade causes chondrodysplasia in a col2a1 p.gly1170ser mutated mouse model. PLoS ONE, 9:e86894, Jan 2014. URL: https://doi.org/10.1371/journal.pone.0086894, doi:10.1371/journal.pone.0086894. This article has 45 citations and is from a peer-reviewed journal.

6. (esapa2012amousemodel pages 1-2): Christopher T Esapa, Tertius A Hough, Sarah Testori, Rosie A Head, Elizabeth A Crane, Carol PS Chan, Holly Evans, JH Duncan Bassett, Przemko Tylzanowski, Eugene G McNally, Andrew J Carr, Alan Boyde, Peter GT Howell, Anne Clark, Graham R Williams, Matthew A Brown, Peter I Croucher, M Andrew Nesbit, Steve DM Brown, Roger D Cox, Michael T Cheeseman, and Rajesh V Thakker. A mouse model for spondyloepiphyseal dysplasia congenita with secondary osteoarthritis due to a col2a1 mutation. Journal of Bone and Mineral Research, 27:413-428, Feb 2012. URL: https://doi.org/10.1002/jbmr.547, doi:10.1002/jbmr.547. This article has 44 citations and is from a highest quality peer-reviewed journal.

7. (yammine2023erprocollagenstorage pages 9-12): Kathryn M. Yammine, Sophia Mirda Abularach, Seo-yeon Kim, Agata A. Bikovtseva, Jinia Lilianty, Vincent L. Butty, Richard P. Schiavoni, John F. Bateman, Shireen R. Lamandé, and Matthew D. Shoulders. Er procollagen storage defect without coupled unfolded protein response drives precocious arthritis. BioRxiv, Oct 2024. URL: https://doi.org/10.1101/2023.10.19.562780, doi:10.1101/2023.10.19.562780. This article has 5 citations.

8. (yammine2023erprocollagenstorage pages 1-5): Kathryn M. Yammine, Sophia Mirda Abularach, Seo-yeon Kim, Agata A. Bikovtseva, Jinia Lilianty, Vincent L. Butty, Richard P. Schiavoni, John F. Bateman, Shireen R. Lamandé, and Matthew D. Shoulders. Er procollagen storage defect without coupled unfolded protein response drives precocious arthritis. BioRxiv, Oct 2024. URL: https://doi.org/10.1101/2023.10.19.562780, doi:10.1101/2023.10.19.562780. This article has 5 citations.

9. (liang2014endoplasmicreticulumstressunfolding pages 5-9): Guo-yan Liang, Chengjie Lian, Di Huang, Wenjie Gao, Anjing Liang, Yan Peng, Wei Ye, Zizhao Wu, Peiqiang Su, and Dongsheng Huang. Endoplasmic reticulum stress-unfolding protein response-apoptosis cascade causes chondrodysplasia in a col2a1 p.gly1170ser mutated mouse model. PLoS ONE, 9:e86894, Jan 2014. URL: https://doi.org/10.1371/journal.pone.0086894, doi:10.1371/journal.pone.0086894. This article has 45 citations and is from a peer-reviewed journal.

10. (yammine2023erprocollagenstorage pages 15-18): Kathryn M. Yammine, Sophia Mirda Abularach, Seo-yeon Kim, Agata A. Bikovtseva, Jinia Lilianty, Vincent L. Butty, Richard P. Schiavoni, John F. Bateman, Shireen R. Lamandé, and Matthew D. Shoulders. Er procollagen storage defect without coupled unfolded protein response drives precocious arthritis. BioRxiv, Oct 2024. URL: https://doi.org/10.1101/2023.10.19.562780, doi:10.1101/2023.10.19.562780. This article has 5 citations.

11. (liang2014endoplasmicreticulumstressunfolding media a802b0c3): Guo-yan Liang, Chengjie Lian, Di Huang, Wenjie Gao, Anjing Liang, Yan Peng, Wei Ye, Zizhao Wu, Peiqiang Su, and Dongsheng Huang. Endoplasmic reticulum stress-unfolding protein response-apoptosis cascade causes chondrodysplasia in a col2a1 p.gly1170ser mutated mouse model. PLoS ONE, 9:e86894, Jan 2014. URL: https://doi.org/10.1371/journal.pone.0086894, doi:10.1371/journal.pone.0086894. This article has 45 citations and is from a peer-reviewed journal.

12. (liang2014endoplasmicreticulumstressunfolding media 7e048216): Guo-yan Liang, Chengjie Lian, Di Huang, Wenjie Gao, Anjing Liang, Yan Peng, Wei Ye, Zizhao Wu, Peiqiang Su, and Dongsheng Huang. Endoplasmic reticulum stress-unfolding protein response-apoptosis cascade causes chondrodysplasia in a col2a1 p.gly1170ser mutated mouse model. PLoS ONE, 9:e86894, Jan 2014. URL: https://doi.org/10.1371/journal.pone.0086894, doi:10.1371/journal.pone.0086894. This article has 45 citations and is from a peer-reviewed journal.

13. (liang2014endoplasmicreticulumstressunfolding media 4409704f): Guo-yan Liang, Chengjie Lian, Di Huang, Wenjie Gao, Anjing Liang, Yan Peng, Wei Ye, Zizhao Wu, Peiqiang Su, and Dongsheng Huang. Endoplasmic reticulum stress-unfolding protein response-apoptosis cascade causes chondrodysplasia in a col2a1 p.gly1170ser mutated mouse model. PLoS ONE, 9:e86894, Jan 2014. URL: https://doi.org/10.1371/journal.pone.0086894, doi:10.1371/journal.pone.0086894. This article has 45 citations and is from a peer-reviewed journal.

14. (liang2014endoplasmicreticulumstressunfolding media 919d3da4): Guo-yan Liang, Chengjie Lian, Di Huang, Wenjie Gao, Anjing Liang, Yan Peng, Wei Ye, Zizhao Wu, Peiqiang Su, and Dongsheng Huang. Endoplasmic reticulum stress-unfolding protein response-apoptosis cascade causes chondrodysplasia in a col2a1 p.gly1170ser mutated mouse model. PLoS ONE, 9:e86894, Jan 2014. URL: https://doi.org/10.1371/journal.pone.0086894, doi:10.1371/journal.pone.0086894. This article has 45 citations and is from a peer-reviewed journal.

15. (yammine2023erprocollagenstorage pages 12-15): Kathryn M. Yammine, Sophia Mirda Abularach, Seo-yeon Kim, Agata A. Bikovtseva, Jinia Lilianty, Vincent L. Butty, Richard P. Schiavoni, John F. Bateman, Shireen R. Lamandé, and Matthew D. Shoulders. Er procollagen storage defect without coupled unfolded protein response drives precocious arthritis. BioRxiv, Oct 2024. URL: https://doi.org/10.1101/2023.10.19.562780, doi:10.1101/2023.10.19.562780. This article has 5 citations.

16. (yammine2024erprocollagenstoragea pages 83-88): KM Yammine, S Mirda Abularach, and S Kim. Er procollagen storage defect without associated unfolded protein response drives precocious osteoarthritis. Unknown journal, 2024.

17. (morales2025theuseof pages 38-42): LC Vertel Morales. The use of human induced pluripotent stem cells to model type 2 collagenopathies. Unknown journal, 2025.

18. (akahiraazuma2022novelcol2a1variants pages 1-2): Moe Akahira-Azuma, Yumi Enomoto, Naoyuki Nakamura, Takayuki Yokoi, Mari Minatogawa, Noriaki Harada, Yoshinori Tsurusaki, and Kenji Kurosawa. Novel col2a1 variants in japanese patients with spondyloepiphyseal dysplasia congenita. Human Genome Variation, May 2022. URL: https://doi.org/10.1038/s41439-022-00193-x, doi:10.1038/s41439-022-00193-x. This article has 4 citations.

Comprehensive Pathophysiological Analysis of Spondyloepiphyseal Dysplasia Congenita

Spondyloepiphyseal dysplasia congenita (SEDC) is a rare autosomal dominant skeletal dysplasia with a prevalence of approximately 3.4 per million individuals that results from mutations in the COL2A1 gene encoding type II collagen[1]. The condition is characterized by disproportionate short stature with preferential shortening of the trunk, abnormal epiphyseal development, platyspondyly (flattened vertebral bodies), and multisystem involvement including significant ocular and auditory manifestations[7]. The fundamental pathophysiological basis of SEDC involves aberrant synthesis, folding, and assembly of type II collagen molecules, leading to impaired extracellular matrix formation, endoplasmic reticulum (ER) stress, chondrocyte dysfunction, and ultimately compromised skeletal development and growth. This report comprehensively examines the molecular mechanisms underlying SEDC pathogenesis, the affected cellular and tissue systems, the progression from genetic mutations to clinical phenotypes, and the current understanding of structure-function relationships in COL2A1-related disease.

Molecular Basis and Genetic Architecture of SEDC

The COL2A1 Gene and Type II Collagen Structure

The COL2A1 gene, located on chromosome 12q13.11 to 12q13.2, spans over 31.5 kilobases and contains 54 exons encoding a 1487-amino acid protein that assembles into type II collagen[43]. Type II collagen represents the predominant structural component of hyaline cartilage, comprising approximately 95 percent of total cartilage collagen and roughly 60 percent of the dry weight of articular cartilage in adults[28][43]. Beyond its cartilaginous distribution, type II collagen is also found abundantly in the nucleus pulposus of intervertebral discs, the vitreous humor of the eye, and inner ear structures, which explains the pleiotropic nature of SEDC manifestations affecting the skeletal, ocular, and auditory systems[28][43]. The structural organization of type II collagen consists of three identical α1(II) polypeptide chains of approximately 1060 amino acid residues each, which associate to form a characteristic triple helix through electrostatic interactions and interchain disulfide bonding[43]. The protein contains a large central triple-helical region characterized by repeating Gly-X-Y tripeptide sequences, where glycine occupies the every-third amino acid position (essential for helix formation due to its minimal side chain), and the X and Y positions are frequently occupied by proline and hydroxyproline residues respectively[28][32][43]. Flanking the triple-helical core are relatively short non-helical telopeptide regions: the N-telopeptide consisting of 19 amino acid residues and the C-telopeptide comprising 27 amino acid residues[43]. These telopeptide regions, which lack the characteristic Gly-X-Y repeating structure, are crucial for initiating triple-helical configuration and for subsequent cross-linking of collagen molecules in the extracellular matrix[28][43].

Mutational Spectrum and Classification

Over 100 distinct COL2A1 mutations have been identified in SEDC patients, with the majority representing missense mutations accounting for more than 70 percent of reported variants[28][32]. Approximately 74 percent of mutations result in glycine substitutions within the triple-helical domain, representing the most common pathogenic mechanism, while 10 percent involve arginine-to-cysteine (Arg-to-Cys) substitutions[28][32]. These glycine substitutions are particularly deleterious because they violate the essential structural requirement of the Gly-X-Y tripeptide repeat—only glycine, with its single hydrogen atom as a side chain, can fit within the sterically restricted interior of the collagen triple helix, and any substitution with larger amino acids results in structural disruption[29][43]. Only a small proportion of mutations (approximately 5-15 percent) involve the C-propeptide region, which is important for procollagen assembly and trimerization[28][32]. Truncating mutations, including nonsense mutations and frameshift mutations, account for a minority of SEDC cases but represent an important functional class[28][29]. Notably, most nonsense mutations in SEDC occur in the last exon (exon 54) of the COL2A1 gene, allowing them to escape nonsense-mediated decay (NMD), which would otherwise degrade aberrant transcripts; this escape from NMD permits production of truncated collagen proteins with potential dominant-negative effects[29].

The fundamental pathophysiological dichotomy in type II collagen mutations involves two primary molecular mechanisms of disease inheritance[28][32][43]. The first mechanism, dominant-negative effects, occurs predominantly with glycine substitutions and involves production of aberrant collagen proteins that interfere with normal collagen assembly and function when co-assembled with wild-type chains in the heterotrimeric collagen molecule[28][32]. The second mechanism, haploinsufficiency, occurs with nonsense and out-of-frame deletion mutations that generate premature stop codons, resulting in reduced synthesis of normal type II collagen protein due to NMD or translation termination[28][32]. Haploinsufficiency-mediated mutations generally produce milder phenotypes than dominant-negative mechanisms because the body can partially compensate with approximately 50 percent of normal collagen levels, whereas dominant-negative effects can incapacitate higher proportions of total collagen through mixed oligomeric assembly[28][32].

Cellular Pathophysiology and Intracellular Mechanisms

Procollagen Synthesis and Biosynthesis Defects

The synthesis and secretion of functional type II collagen represents a complex multistep biosynthetic pathway that is profoundly disrupted in SEDC. Within the endoplasmic reticulum (ER) of chondrocytes, the COL2A1 gene is transcribed and translated to produce pro-α1(II) chains that undergo extensive post-translational modifications including hydroxylation of proline and lysine residues by prolyl 4-hydroxylase (P4H) and lysyl hydroxylase respectively[32][43]. These hydroxylation reactions are essential modifications required for thermal stability of the collagen triple helix and for subsequent cross-linking in the extracellular matrix[32][43]. In normal collagen biosynthesis, the three pro-α1(II) chains associate into triple-helical procollagen molecules through a process that is highly regulated by ER-resident protein chaperones including heat shock protein 47 (HSP47), immunoglobulin-binding protein (BiP), and protein disulfide isomerase (PDI)[12][32]. These molecular chaperones bind to nascent pro-α1(II) chains and facilitate proper folding, preventing premature association and promoting formation of the native triple-helix conformation[12][32]. In SEDC caused by glycine substitutions, the mutation disrupts the critical geometry of the triple-helical structure, preventing proper strand alignment and helix formation[29]. Structural studies demonstrate that mutant type II collagen molecules display altered electrophoretic mobility, relatively low thermostability compared to wild-type collagen, and slow rates of secretion into the extracellular space[28][32]. The impaired thermostability indicates that mutant collagen trimers are more readily susceptible to unfolding or denaturation, even at physiological temperatures[32].

A particularly important feature of SEDC mutations involving glycine-to-arginine or other charged substitutions is the formation of aberrant intramolecular disulfide bonds within the misfolded collagen chains[12][32][47]. In the R992C (arginine-to-cysteine at position 992) mouse model of SEDC, biochemical analysis revealed the presence of intramolecular disulfide cross-links within mutant collagen molecules, whereas wild-type collagen lacks such linkages[47]. These aberrant disulfide bonds represent failed attempts at proper protein folding, whereby the cysteines form intermolecular covalent bonds in misguided locations, further stabilizing the non-native collagen conformation and preventing recovery to proper structure[47]. The presence of these aberrant cross-links correlates with marked impairment in the protein's ability to form functional triple-helical structures and contributes to intracellular retention of the mutant collagen[47].

Endoplasmic Reticulum Stress and Unfolded Protein Response

One of the central pathophysiological mechanisms underlying SEDC pathogenesis involves activation of the endoplasmic reticulum stress response and the unfolded protein response (UPR)[15][29][32][36]. The accumulation of misfolded mutant type II collagen within the ER lumen represents a potent trigger for cellular stress, activating the three primary UPR sensors: inositol-requiring enzyme 1α (IRE1α), protein kinase R (PKR)-like ER kinase (PERK), and activating transcription factor 6 (ATF6)[15][29][32]. When mutant collagen molecules remain retained in the ER and cannot be properly folded or secreted, these ER stress sensors undergo activation through various mechanisms including oligomerization and autophosphorylation, ultimately leading to coordinated changes in gene expression designed to restore ER homeostasis[29][32].

Recent mechanistic studies have illuminated the specific molecular events in SEDC-related ER stress. In transgenic mouse models with the R992C collagen II mutation, chondrocytes exhibited greatly extended cisternae of rough endoplasmic reticulum containing retained procollagen and fibronectin, with accumulation of mutant collagen creating sufficient ER stress to substantially reduce the proliferation rate of chondrocytes at the growth plate[28][32]. Molecular analysis of these chondrocytes revealed elevated expression of multiple ER stress markers including binding immunoglobulin protein (BiP), protein disulfide isomerase (PDI), and activating transcription factor 4 (ATF4)[28][32]. The increased abundance of BiP and PDI in response to mutant collagen indicates enhanced recruitment of molecular chaperones attempting to refold the misfolded collagen chains[28][47]. Interestingly, detailed subcellular localization studies demonstrated differential effects on chaperone distribution: there was increased colocalization of PDI with misfolded R992C procollagen, suggesting that PDI preferentially binds to the nascent aberrant chains, while BiP showed decreased colocalization with the mutant procollagen, potentially due to blocked binding sites resulting from altered triple-helix structure[47].

The consequences of sustained ER stress in SEDC chondrocytes extend beyond simple protein folding defects to encompass broader cellular dysfunction. The persistent activation of the UPR, while initially cytoprotective, can transition into a pro-apoptotic program if ER stress remains unresolved[15][32][33]. The PERK branch of the UPR, activated through its autophosphorylation in response to unfolded proteins, leads to phosphorylation of eukaryotic initiation factor 2 alpha (eIF2α), which globally attenuates translation to reduce the protein synthesis burden on the ER[15][32][33]. However, paradoxically, specific transcription factors including activating transcription factor 4 (ATF4) and particularly C/EBP homologous protein (CHOP) are translated despite eIF2α phosphorylation through upstream open reading frame mechanisms[15][33]. CHOP acts as a master regulator of ER stress-induced apoptosis, translocating to the nucleus and inducing expression of pro-apoptotic genes including those encoding BH3-only proteins and the death receptor pathway components[15][33]. In SEDC chondrocytes, elevated CHOP expression downstream of PERK activation has been documented to drive increased apoptosis through the intrinsic mitochondrial apoptosis pathway, involving the pro-apoptotic protein Bax and the BH3-only proteins, ultimately activating the caspase cascade[15][33].

A recent discovery has identified a crucial role for the DDRGK1 protein in maintaining ER homeostasis during collagen biosynthesis[15]. DDRGK1 (DDRGK1 domain-containing protein), localized to the endoplasmic reticulum membrane, functions to stabilize IRE1α through a previously unrecognized UFMylation mechanism (ubiquitin-fold modifier UFM1 conjugation)[15]. In mouse models with conditional knockout of DDRGK1 specifically in chondrocytes, the loss of this protein led to decreased UFMylation of IRE1α, which subsequently promoted ubiquitin-mediated degradation of IRE1α[15]. This degradation of the IRE1α stress sensor paradoxically caused ER dysfunction and activation of the PERK/CHOP/Caspase3 apoptosis pathway, ultimately impairing normal chondrogenesis[15]. These findings suggest that in SEDC, not only does the collagen mutation trigger ER stress, but additional vulnerabilities in the ER stress response machinery itself may compound the cellular dysfunction.

Secretion Defects and Extracellular Matrix Assembly

Following attempted folding in the ER, mutant type II collagen molecules that partially escape ER retention face considerable challenges during the secretory pathway. The export of procollagen from the ER into the Golgi and secretory vesicles involves highly specialized mechanisms distinct from conventional secretory protein transport. Recent research has identified the TANGO1 protein (Transport and Golgi Organization) and associated factors as critical mediators of large procollagen export from the ER[44]. TANGO1 and its binding partner cTAGE5 function at specialized ER exit sites (ERES) to recognize and concentrate procollagen trimers, recruiting ERGIC (ER-Golgi intermediate compartment) membranes and COPII coat components to facilitate export of mega-carriers containing multiple procollagen molecules[44]. In SEDC, the impaired folding and assembly of mutant collagen molecules likely disrupts their recognition by the TANGO1-mediated export machinery, resulting in their preferential retention within the ER rather than transit through the secretory pathway[44].

When mutant type II collagen molecules do successfully transit to the extracellular space—which occurs at reduced rates compared to wild-type collagen—they fail to assemble into normal fibrillar networks[28][32]. Instead, these molecules self-assemble into abnormal fibrillar structures that are incapable of proper interaction with other extracellular matrix components and supporting proteins[28][32]. Electron microscopic and biochemical analyses of SEDC mouse cartilage have revealed decreased fibril diameter compared to wild-type cartilage, coupled with increased amorphous material and reduced numbers of collagen fibrils overall[28][32][45]. Furthermore, mutant type II collagen exhibits impaired cross-linking by lysyl oxidase and related enzymes, as the aberrant collagen conformation makes the critical lysine and hydroxylysine residues that serve as cross-linking substrates less accessible or in incorrect three-dimensional orientations[28][32]. The result is a disorganized, mechanically compromised extracellular matrix that cannot provide the normal scaffolding essential for cartilage integrity and load-bearing function.

Tissue-Level Pathophysiology

Cartilage Development and Growth Plate Dysfunction

The growth plate represents the primary site of longitudinal bone growth and is consequently one of the most severely affected tissues in SEDC. Histopathological examination of growth plate cartilage from SEDC patients and animal models reveals dramatic alterations in the normal columnar organization and cell-matrix relationships that characterize healthy endochondral ossification[28][32]. The proliferative and hypertrophic zones of the growth plate cartilage are markedly shortened or sometimes nearly indistinguishable from one another[28][32]. Deposition of the extracellular cartilage matrix is severely impaired, with collagen fibrils being fewer in number and less elaborate in their packing arrangements[28][32]. This defective matrix deposition impairs the mechanical properties of the growth plate and compromises the three-dimensional organization required for coordinated chondrocyte differentiation and advancement through the successive developmental stages[28][32].

The proper fibrillar architecture and biomechanical characteristics of the interterritorial and pericellular collagenous matrix within the growth plate are absolutely critical for maintaining correct columnar arrangement of chondrocytes[28][32]. In SEDC, the presence of disorganized and mechanically compromised mutant collagen fails to provide the necessary structural cues, resulting in disruption of the highly ordered columnar cell arrangements that normally characterize healthy growth plate zones[28][32]. This disorganization disrupts cell-cell and cell-matrix signaling that orchestrates the normal progression of chondrocyte differentiation. Additionally, the retention of misfolded procollagen in chondrocytes creates severe ER stress sufficient to reduce the proliferation rate at the growth plates, directly limiting the expansion of the proliferative chondrocyte population that normally occurs through rapid cell division[28][32].

Gene expression studies in SEDC growth plates reveal marked disturbances in the transcriptional programs driving chondrocyte differentiation and function. Molecular analysis has documented absence or marked reduction in messenger RNA expression of critical chondrocyte differentiation markers including cyclin-dependent kinase inhibitor 1A (Cdkn1a), Indian hedgehog (Ihh), fibroblast growth factor receptor 3 (Fgfr3), type X collagen (COL10A1), and the osteogenic transcription factor Runx2[28][32]. These reductions in marker gene expression indicate that the normal progression of chondrocyte differentiation—from proliferative to hypertrophic to terminal differentiation stages—is severely disrupted in SEDC[28][32]. The abnormal chondrocyte differentiation further negatively affects linear bone growth by altering normal cell relationships and disrupting the provision of critical growth factors during the endochondral ossification process[28][32].

Recent work has clarified the role of type II collagen itself as an important autocrine regulator of chondrocyte proliferation and differentiation. Type II collagen acts as an autocrine factor promoting chondrocyte proliferation and differentiation through multiple downstream effector pathways, while simultaneously serving as a potent suppressor of inappropriate chondrocyte hypertrophy and apoptosis through negative regulation of SMAD1 signaling[28]. In SEDC, the presence of aberrant, non-functional mutant collagen fails to provide these critical autocrine regulatory signals, further contributing to dysregulated chondrocyte differentiation and increased apoptosis[28].

Skeletal Manifestations and Bone Development

The pathophysiology underlying the skeletal manifestations of SEDC extends beyond the growth plate to involve disruption of normal endochondral ossification throughout the skeleton[28][32]. Endochondral ossification, the fundamental process by which most bones develop and by which long bones increase in length, depends on coordinated resorption of the cartilage template and replacement with bone matrix[14][17]. Recent lineage-tracing studies have revealed that many, perhaps the majority, of bone cells derive from the direct transformation of hypertrophic chondrocytes rather than from invasion of mesenchymal progenitors, establishing a chondrocyte-to-osteoblast continuum[14][17]. In this process, hypertrophic chondrocytes undergo transdifferentiation, expressing osteogenic genes including Col1a1 (type I collagen) and Osx (osterix) transcription factor, and ultimately become integrated into the bone matrix as osteocytes[14][17].

In SEDC, this critical chondrocyte-to-osteoblast transition is severely compromised. The defective cartilage matrix created by mutant type II collagen provides an inadequate structural template for this transformation and fails to provide appropriate signaling cues for the differentiation program[28][32]. Additionally, the ER stress and apoptosis occurring in SEDC chondrocytes likely triggers premature cell death before these cells can successfully complete their transdifferentiation into bone-forming cells[28][32]. The result is impaired endochondral ossification, leading to delayed and dysplastic ossification of epiphyseal centers, short long bones with abnormal shapes, and compromised overall skeletal development[28][32].

The spine represents a particularly severely affected skeletal structure in SEDC, with characteristic radiological findings including platyspondyly (flattened vertebral bodies), disc space narrowing, irregular vertebral body endplates, and progressive kyphoscoliosis[27][38][42]. These spinal manifestations reflect impaired endochondral ossification of vertebral bodies and disrupted chondrocyte development in the growth plates of the spine[28][32]. The reduced height and irregular shape of vertebral bodies creates biomechanical instability and malalignment of the spine[27][38]. Additionally, defective ossification of the odontoid process (dens) of the second cervical vertebra frequently occurs in SEDC, leading to odontoid hypoplasia or even os odontoideum (an os odontoideum is a remnant of the odontoid process separated from the axis vertebra)[27][38]. This cervical spine pathology creates the risk of atlantoaxial instability and cervical myelopathy, representing one of the most significant medical complications of SEDC[27][38].

The proximal femur is another severely affected skeletal region, with characteristic findings including dysplasia of the femoral head epiphysis, delayed ossification of the femoral head (often not appearing radiographically until after age 5 or even much later), and development of coxa vara (inward angulation of the femoral neck)[27][38]. The dysplastic femoral head fails to develop into a proper spherical shape, instead remaining irregular and fragmented[27][38]. These hip dysplasias create significant biomechanical derangement, leading to poor weight distribution, high contact stresses, and early-onset osteoarthritis[27][38]. Most SEDC patients eventually undergo total hip arthroplasty by an average age of 40 years due to severe osteoarthritis[27][38].

Ocular Manifestations and Vitreoretinal Pathology

Type II collagen's abundant distribution in ocular tissues explains the frequent and sometimes severe vision problems that accompany SEDC. Severe nearsightedness (high myopia) is reported in a substantial proportion of SEDC patients, with myopic refraction of 5.00 diopters or greater being common[22][53]. The myopia in SEDC results from defective type II collagen in structures of the eye including the neural retina, optic vesicle, sclera, and conjunctival epithelium[1][9]. The structural role of type II collagen in maintaining the normal shape and refractive properties of the eye is compromised when collagen is aberrant, leading to alterations in axial length or corneal curvature that result in myopic refraction[1].

Beyond myopia, significant vitreoretinal degeneration represents a characteristic and sometimes vision-threatening manifestation of SEDC. Postmortem histopathologic and electron microscopic examination of eyes from SEDC patients has revealed extensive pathology including central liquefaction of the vitreous, multifocal areas of vitreous detachment exerting traction on the retina, a thin and discontinuous internal limiting membrane (the basement membrane between the vitreous and retina), preretinal cellular proliferation, and small areas of retinoschisis (splitting of retinal layers)[19][50]. These findings indicate that the vitreoretinal interface is fundamentally destabilized by defective type II collagen, compromising the normal gel structure of the vitreous and the integrity of the internal limiting membrane[19][50].

While historical reports in non-ophthalmologic literature have claimed retinal detachment rates as high as 50 percent in SEDC, more recent ophthalmologic studies examining carefully characterized SEDC patients report lower actual rates of clinical retinal detachment, though the risk remains substantially elevated compared to the general population[53]. The mechanism of increased retinal detachment risk involves the vitreous syneresis and traction observed in SEDC eyes, wherein mechanical forces exerted through abnormal vitreous attachments can eventually lead to full retinal breaks and detachment[19][53]. Additionally, myopic patients generally carry higher baseline risks for retinal complications including myopic choroidal neovascularization and posterior staphyloma formation (outward bulging of the posterior eye wall)[53].

Auditory System Pathology and Hearing Loss

Hearing loss occurs in an estimated 25 to 30 percent of SEDC patients, representing a significant but variable extraosseous manifestation of the disease[20][22][23]. Most reports have documented sensorineural hearing loss as the predominant type of hearing impairment in SEDC, reflecting involvement of the inner ear structures where type II collagen is abundant in the matrix surrounding sensory cells of the cochlea and vestibular apparatus[20][22][23]. However, at least one case report documented conductive hearing loss with a Carhart notch (a characteristic depression in the bone conduction audiogram between 2000-4000 Hz), indicating stapes footplate fixation presumably resulting from ossification of the stapedial footplate or related ossicular pathology[20]. This case suggests that middle ear ossification abnormalities may also occur in some SEDC patients, though sensorineural hearing loss remains more common[20].

The pathophysiology of inner ear involvement in SEDC likely involves similar mechanisms to those affecting other cartilaginous structures: disruption of the specialized extracellular matrices that comprise the inner ear, ER stress and dysfunction of sensory cell progenitors during otic development, and possibly direct effects on auditory sensory cells and vestibular cells during their differentiation and maturation[22][28]. The temporal bone and inner ear develop through complex endochondral ossification processes that require properly functioning type II collagen for normal structural development[28].

Disease Progression and Developmental Trajectory

Prenatal and Neonatal Manifestations

The manifestations of SEDC typically emerge during fetal development, with radiological findings often evident on prenatal ultrasound, and clinical abnormalities becoming apparent at or immediately following birth[1][7]. The word "congenita" in the disorder's name specifically indicates that the condition is generally noticeable at birth, distinguishing it from the milder variant spondyloepiphyseal dysplasia tarda (SEDT), where manifestations typically do not become apparent until 6 to 8 years of age[27][31]. Some SEDC infants present with severe respiratory distress shortly after birth, particularly if they have an extremely underdeveloped or small rib cage and abnormal thoracic cage development[31]. The narrow barrel-shaped chest that characterizes SEDC can restrict rib cage expansion and prevent the lungs from fully inflating, creating a restrictive lung disease pattern[31]. Additionally, some patients have tracheomalacia (weakness and abnormal collapse of the tracheal airways), which further compromises the ability to maintain adequate airway patency and ventilation[22][55].

At birth, infants with SEDC present with obvious disproportionate short stature, with particularly shortened trunk and neck compared to the extremities[1][7][22]. Characteristic facial features include a broad, flat face with underdeveloped cheekbones (malar hypoplasia), micrognathia (small lower jaw), and glossoptosis (posterior positioning of the tongue)[7][22][25]. Some infants exhibit the complete Pierre Robin sequence, which includes cleft palate in conjunction with the micrognathia and glossoptosis[7][22]. The presence of cleft palate occurs in a substantial proportion of SEDC cases and reflects disrupted development of the palatal structures during embryogenesis due to defective type II collagen in developing palatal mesenchyme and epithelium[21][28].

Childhood Progressive Features

As children with SEDC grow, additional skeletal and extraosseous manifestations emerge and progressively worsen. Progressive kyphoscoliosis develops in many SEDC patients, with over 50 percent eventually developing severe scoliosis requiring surgical intervention[27][38]. The progressive spinal deformity results from ongoing disruption of normal vertebral body development and asymmetric growth of the spine[27][38]. Importantly, cervical spine instability can emerge during childhood or may already be present at birth in infants with odontoid process dysplasia; this instability requires careful monitoring as it carries significant risk for myelopathy if not appropriately managed[27][38].

Limb deformities progress during childhood as abnormal ossification of epiphyses continues and growth plates remain dysfunctional[27][38]. Coxa vara of the hip progressively worsens, with increasing degrees of varus angulation often accompanied by substantial hip flexion contractures[27][38]. Genu valgum (knock-knees) and genu varum (bow-legs) develop as the distal femur and proximal tibia undergo dysplastic ossification[7][27]. Clubfoot deformities, when present at birth, may require orthopedic intervention[7][27]. Joint mobility progressively decreases in the hips, knees, elbows, and shoulders as cartilage degeneration begins during childhood and stiffness develops[7][27].

The vision problems that characterize SEDC frequently progress during the adolescent years. Myopia may progress as the eye continues to grow, and retinal detachment risks appear to be particularly high during adolescence as rapid skeletal growth continues and eyes undergo further remodeling[22][53][55]. Regular ophthalmologic examinations during childhood and adolescence are therefore critically important for SEDC patients to detect retinal complications early and facilitate timely interventions[55].

Adulthood and Late Complications

By adulthood, many SEDC patients experience severe osteoarthritis, particularly affecting the hip and knee joints where dysplastic epiphyseal development during childhood has created abnormal joint mechanics[27][31]. Hip and knee pain often necessitates surgical intervention, with many patients ultimately requiring total joint arthroplasty[27][31][38]. The average age for total hip replacement in SEDC patients is approximately 40 years, far younger than typical for idiopathic osteoarthritis[27][38].

Additionally, adult SEDC patients are at risk for serious complications related to cervical spine pathology. Even if atlantoaxial instability was recognized and surgically stabilized in childhood, patients may develop progressive cervical myelopathy from continued cervical stenosis, disc space narrowing, or late instability[27][38][55]. Respiratory complications may also emerge or worsen with age; while early childhood respiratory difficulties often improve as the child grows, restrictive lung disease can persist or develop in adulthood due to the abnormal thoracic cage, potentially progressing to sleep apnea and chronic respiratory insufficiency[31][55].

Genotype-Phenotype Relationships and Mutation-Specific Pathophysiology

Glycine Substitutions and Dominant-Negative Mechanisms

The pathophysiological consequences of SEDC mutations vary significantly based on the specific type and location of the mutation within the COL2A1 gene. Glycine substitution mutations, which account for approximately 74 percent of SEDC-causing variants and are predominantly located within the triple-helical domain, consistently produce the most severe phenotypes[28][32][43]. The fundamental reason for the severity of glycine substitutions relates to the unique structural role of glycine in the collagen triple helix: only glycine's minimal hydrogen atom side chain can accommodate the restricted geometry of the helix interior, and substitution with any larger amino acid residue creates steric clashes that prevent proper helix formation[29][43]. The most common glycine substitutions in SEDC involve replacement with arginine or other charged amino acids, which not only violate the steric requirements but also introduce electrostatic disruptions to the hydrophobic helix core[29][43].

A critical feature distinguishing glycine substitutions from other SEDC mutations is their dominant-negative mechanism of action[28][32][43]. Type II collagen is a homotrimeric molecule composed of three identical α1(II) chains that must properly associate and fold to form a functional triple helix. During heterotrimeric assembly in cells expressing both wild-type and mutant alleles (as occurs in heterozygous SEDC patients), the three collagen chains are randomly selected from a pool containing both wild-type and mutant proteins. Therefore, trimers can form with variable combinations: wild-type/wild-type/wild-type (all normal), wild-type/wild-type/mutant (one mutant), wild-type/mutant/mutant (two mutants), or mutant/mutant/mutant (all mutant). Statistically, only approximately 12.5 percent of trimers will be entirely wild-type, while 87.5 percent will contain at least one mutant chain[32]. Each mutant chain within a trimer has the potential to disrupt triple-helix formation for the entire molecule, rendering the entire trimer defective[32]. This dominant-negative effect explains why heterozygous mutations can produce such severe disease phenotypes despite 50 percent of the alleles being normal[28][32][43].

The consequences of this dominant-negative action are compounded by the retention of misfolded mutant trimers within the ER. As detailed in the cellular pathophysiology section, these retained molecules accumulate to concentrations sufficient to trigger robust ER stress responses that can trigger chondrocyte apoptosis[28][32]. The combination of reduced secretion of functional collagen (because most trimers contain at least one mutant chain) and cellular toxicity from ER stress creates a particularly severe pathophysiological state[28][32].

Arginine-to-Cysteine Substitutions

Approximately 10 percent of SEDC mutations involve substitution of arginine residues with cysteine, most commonly in the Y positions of Gly-X-Y tripeptides (where arginine substitutions in positions 275, 719, 989 have been documented)[28][32]. The R989C mutation has been identified in multiple unrelated SEDC families and represents one of the well-characterized recurring mutations[28][32]. The pathophysiology of arginine-to-cysteine substitutions differs somewhat from glycine substitutions, as these alterations occur at non-glycine positions and therefore do not as severely disrupt the basic geometry of the triple helix[28][32]. However, arginine residues at Y positions in Gly-X-Y tripeptides frequently form critical interchain hydrogen bonds and electrostatic interactions essential for trimer stability; replacing these arginines with cysteine eliminates these stabilizing interactions while introducing a thiol group capable of forming aberrant intramolecular and intermolecular disulfide bonds[28][32][47].

As demonstrated in molecular studies of the R992C mutation (which corresponds to R989C when accounting for different reference frames), arginine-to-cysteine substitutions result in formation of aberrant intermolecular disulfide bonds that trap collagen trimers in misfolded conformations[47]. These disulfide-linked oligomeric complexes are retained within the ER and resist unfolding and refolding attempts by molecular chaperones[47]. While arginine-to-cysteine substitutions generally produce less severe phenotypes than glycine substitutions, they still result in significant SEDC manifestations[28][32].

Non-Glycine Missense Mutations

Missense mutations not involving glycine substitution in the triple-helical domain generally produce milder SEDC phenotypes compared to glycine substitutions[28][32]. These mutations cause impairment in protein stability through various mechanisms including disruption of electrostatic interactions, disruption of post-translational modification sites, or alteration of hydrophobic packing interactions[28][32]. The pathophysiology of non-glycine missense mutations involves primarily compromised protein stability and subsequently impaired triple-helix formation and function, rather than the severe steric disruptions caused by glycine substitutions[28][32]. These mutations are more likely to allow formation of some proportion of functional collagen trimers compared to glycine substitutions, potentially mitigating disease severity[28][32].

C-Propeptide Mutations and Rare Phenotypes

A small subset of SEDC mutations involve the C-propeptide domain near the carboxy-terminal end of the collagen molecule[26][28]. The C-propeptide plays important roles in procollagen trimerization, providing recognition sites for the enzymes that process procollagen into mature collagen, and potentially serving signaling functions[26][28]. Mutations in the C-propeptide region can produce distinctive phenotypes that may differ from classical SEDC and include features such as brachydactyly (short hands and feet), which is relatively rare in other forms of COL2A1-related disease[26][28]. The pathophysiology of C-propeptide mutations involves impaired procollagen assembly and processing rather than disruption of the triple-helical domain[26][28].

Recessive and De Novo Mutations

While SEDC is classically inherited as an autosomal dominant disorder, rare cases of autosomal recessive inheritance have been documented[7][22][25]. In these recessive cases, affected individuals carry mutations in both COL2A1 alleles and produce only mutant collagen without any wild-type collagen contribution[7][22][25]. The pathophysiology of autosomal recessive SEDC involves complete absence of functional type II collagen due to production solely of aberrant collagen from both mutant alleles[7][22][25]. These recessive cases typically present with more severe skeletal and systemic manifestations compared to many dominant cases[7][22][25].

The vast majority of SEDC cases, however, result from de novo mutations—new mutations that occur during gametogenesis in the parent or early embryonic development—rather than inheritance from an affected parent[1][7][22][25]. These de novo mutations create heterozygous individuals with one normal and one mutant COL2A1 allele[1][7][22][25]. The occurrence of de novo mutations likely reflects the relative rarity of the mutation sites and the high mutational target size represented by the large COL2A1 gene[1][7].

Molecular Phenotyping and Mutation-Specific Pathophysiological Outcomes

Recent molecular studies have begun to correlate specific mutations with distinctive phenotypic presentations, though a complete genotype-phenotype relationship remains incompletely understood. A study examining two novel COL2A1 mutations in Chinese families identified a c.1654G>A mutation (p.Gly552Arg) and a c.3518G>T mutation (p.Gly1173Val), both involving glycine substitutions in the triple-helical domain[54]. The patients with these mutations presented with disproportionate short trunk, kyphosis, lumbar lordosis, hip adduction deformity, flattened vertebral bodies, compressed femoral heads, and radiographic evidence of dysplasia, consistent with classic SEDC phenotypes[54]. The p.Gly813Arg mutation (c.2437G>A) has been identified in both French and Chinese SEDC patients and was previously considered extremely rare, with prior reports suggesting it had been documented in only a single patient; the identification of this mutation in a second population indicates that specific mutations may have broader geographic distribution than initially appreciated[2][8].

Notably, heterogeneity in the severity of skeletal phenotypes has been observed even among patients carrying the same COL2A1 mutation. A study of multiple families with the R989C mutation found that some patients developed typical SEDC phenotypes with severe skeletal dysplasia, while others showed variable severity or atypical presentations[28]. This phenotypic variability despite identical mutations suggests that modifier genes, epigenetic factors, or environmental influences contribute to phenotypic expression in SEDC[28]. Additionally, different mutations affecting different regions of the triple-helix may produce varying degrees of impairment in collagen assembly, with mutations affecting amino acid positions critical for inter-chain interactions potentially producing more severe phenotypes than mutations at less critical positions[28][32].

Tissue-Specific Pathophysiology and Multisystem Involvement

Skeletal Stem Cells and Skeletal Development

Recent research has fundamentally altered our understanding of type II collagen distribution in skeletal tissues. Historically, type II collagen was considered stringently confined to chondrocytes and cartilage tissues, but modern lineage-tracing and molecular studies have demonstrated that type II collagen is also expressed in skeletal stem cells and progenitor cells that give rise to both bone and cartilage[56]. The expression of type II collagen in these skeletal stem/progenitor cells and in bone-forming osteogenic lineage cells indicates that COL2A1 mutations affecting type II collagen would be expected to disrupt not only cartilage development but also bone formation[56]. This expanded understanding explains the comprehensive skeletal dysplasia observed in SEDC, involving both cartilaginous and bony structures[56].

Specialized Connective Tissues Beyond Cartilage and Bone

Type II collagen is also present in specialized connective tissues including the intervertebral discs, where it comprises a major component of the nucleus pulposus matrix[28][43]. Disruption of type II collagen by SEDC mutations would therefore compromise disc matrix integrity, contributing to the disc space narrowing and intervertebral disc degeneration observed in SEDC patients[28][32]. Additionally, type II collagen is a significant component of the inner ear matrix structures critical for proper auditory and vestibular function, explaining the hearing loss and potential inner ear dysfunction documented in some SEDC patients[28][43].

Comparative Pathophysiology: SEDC Versus Related COL2A1-Related Dysplasias

Understanding SEDC pathophysiology is enriched by comparison with related conditions caused by different COL2A1 mutations. Spondyloepiphyseal dysplasia tarda (SEDT), the milder form of spondyloepiphyseal dysplasia, typically results from X-linked mutations in the TRAPPC2 gene (rather than COL2A1 mutations, though X-linked forms of spondyloepiphyseal dysplasia do exist) or from different COL2A1 mutations producing milder phenotypes[27][31][38]. SEDT manifests clinically much later than SEDC, with characteristic features becoming apparent around 6 to 8 years of age rather than at birth[27][31][38]. The delayed onset suggests that the pathophysiological disturbances in SEDT are less severe, allowing normal intrauterine and early postnatal skeletal development to proceed relatively normally before skeletal dysplasia becomes evident[27][38].

In contrast, Kniest dysplasia (also caused by COL2A1 mutations) represents an intermediate form of severity between SEDC and milder phenotypes, characterized by short-trunk dwarfism, scoliosis, platyspondyly, and joint enlargement similar to SEDC but with somewhat different radiological features[28][32]. Kniest dysplasia typically shows more pronounced disproportionate short stature and specific radiological findings including characteristically enlarged epiphyses with distinctive "Swiss cheese" or coronal clefting appearance on imaging[28][32]. These phenotypic differences appear to correlate with the specific location and nature of the COL2A1 mutations causing each disorder[28][32].

Cellular and Molecular Mechanisms in Cartilage Matrix Integrity

Collagen Fibril Architecture and Mechanical Function

The collagen fibrils assembled from type II collagen molecules form an intricate three-dimensional network that provides cartilage with its characteristic mechanical properties and tensile strength[40][45]. The mature collagen fibril possesses a characteristic D-periodic structure with regularly spaced molecular overlap regions and gap regions, reflecting the precise axial alignment of individual collagen molecules within the fibril[37][40]. This D-periodic structure is essential for fibril stability and mechanical competence. In SEDC cartilage, electron microscopic examination reveals markedly altered fibril architecture compared to normal cartilage[28][32][45]. Mutant collagen forms fibrils of decreased diameter compared to wild-type collagen fibrils, and these fibrils are fewer in number and more disorganized in their spatial arrangement[28][32][45]. The altered fibrillar organization directly compromises the mechanical competence of the cartilage matrix, reducing its ability to resist compression and distribute mechanical loads normally[28][32][45].

Cross-linking Defects and Extracellular Matrix Stability

The mature type II collagen fibrils within the extracellular matrix are stabilized through covalent cross-linking reactions mediated by lysyl oxidase and related enzymes[40][45]. These enzymes oxidatively deaminate specific lysine and hydroxylysine residues within the collagen telopeptides, converting them to aldehydes (allysine and hydroxyallysine) that spontaneously condense with other amino acids or aldehydes to form covalent cross-links[40][45]. The most prevalent mature cross-link in cartilage is the trivalent hydroxylysyl pyridinoline (HP) residue, which links between adjacent collagen molecules at two sites: from the N-telopeptide of one molecule to the helix of an adjacent molecule, and from the C-telopeptide to the helix[40][45]. In SEDC, the aberrant conformation of mutant collagen compromises its susceptibility to lysyl oxidase-mediated cross-linking because the critical lysine and hydroxylysine residues are either not properly exposed or are in incorrect three-dimensional orientations relative to the cross-linking enzymes and adjacent collagen molecules[28][32][45]. This cross-linking deficiency results in reduced covalent stabilization of the collagen fibrillar network, further compromising its mechanical properties and stability[28][32][45].

Proteoglycan Interactions and Pericellular Matrix Organization

Hyaluronic acid-binding proteoglycans such as aggrecan are also abundant in cartilage extracellular matrix, where they interact extensively with the type II collagen fibrillar scaffold[40][45]. The anionic sulfated glycosaminoglycan chains of proteoglycans interact electrostatically with cationic sodium ions, which in turn attracts water into the matrix, hydrating it and providing the cartilage with its compressive resistance[40][45]. In SEDC cartilage, the disorganized collagen fibrillar network and reduced number of collagen fibrils limits the ability of proteoglycans to interact properly with the collagen framework[28][32][45]. This disruption results in altered proteoglycan localization, with enlarged pericellular spaces (the region immediately surrounding individual chondrocytes) containing increased amounts of proteoglycan but lacking the normal collagen fibrillar framework[45]. The disorganized matrix creates a "Swiss cheese" appearance on electron microscopy, with amorphous material replacing the normally organized fibrils[28][32][45].

Chondrocytes in SEDC cartilage often display morphological abnormalities including atypical cytoplasmic processes and accumulation of abnormal intracellular material[45]. These cellular changes reflect both the effects of growing in an abnormal extracellular matrix environment lacking proper structural organization and the intracellular stress responses (ER stress and apoptosis) triggered by mutant collagen production[28][32][45].

Conclusion and Future Directions in SEDC Pathophysiology Research

The pathophysiology of spondyloepiphyseal dysplasia congenita represents a paradigmatic example of how a single gene mutation can produce complex multisystem disease through cascading molecular and cellular mechanisms. The fundamental defect—aberrant synthesis and assembly of type II collagen—initiates a pathophysiological cascade encompassing ER stress and unfolded protein response activation, chondrocyte dysfunction and apoptosis, disrupted extracellular matrix assembly, impaired endochondral ossification, and compromised skeletal and extraosseous tissue development[28][32][43]. The severity of this cascade depends critically on the specific nature of the COL2A1 mutation, with glycine substitutions producing the most severe dominant-negative effects and other mutation classes producing more variable phenotypes[28][32][43].

Recent advances in mechanistic understanding have illuminated the important roles of protein chaperones (BiP, PDI, HSP47), ER stress sensors (IRE1α, PERK, ATF6), and downstream effectors (CHOP, XBP1, ATF4) in mediating cellular responses to mutant collagen accumulation[15][29][32][47]. The discovery of DDRGK1's role in stabilizing IRE1α through UFMylation represents a particularly exciting advance, suggesting that enhancing ER stress resilience through DDRGK1-mediated mechanisms might represent a therapeutic target[15]. Future research directions include detailed mechanistic studies of how different SEDC mutations produce variable phenotypes through differential effects on protein stability, ER stress kinetics, and apoptosis thresholds; investigation of potential therapeutic interventions targeting ER stress pathways or enhancing protein quality control; and continued development of cellular and animal models that faithfully recapitulate SEDC pathophysiology for testing novel therapeutics[28][32][43].

The continued characterization of rare mutations and their associated phenotypes will further refine our understanding of genotype-phenotype correlations in SEDC and related COL2A1-associated disorders. Additionally, appreciation of the pleiotropic effects of type II collagen in skeletal stem cells, bone cells, and specialized connective tissues beyond cartilage will continue to expand our understanding of why COL2A1 mutations produce such comprehensive skeletal dysplasia[56]. As our molecular understanding of SEDC deepens, opportunities emerge for development of targeted therapeutic interventions, whether through approaches targeting ER stress and protein quality control, strategies to enhance the residual function of partially functional collagen, or ultimately gene therapy approaches[28][32][43][46]. Until such therapeutics are available, the current management of SEDC remains focused on supportive care, orthopedic interventions for skeletal deformities and progressive osteoarthritis, neurological monitoring for cervical myelopathy, ophthalmological surveillance for retinal complications, and auditory assessment and intervention for hearing loss[55].